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Glossary: Abbreviations & Terms 
 
A&E  Accident and Emergency 
ADP  Alcohol & Drug Partnership 
BBV  Blood-Borne Viruses 
Benzos Benzodiazepine 
BZP  Also known as party pills. Tablets containing benzylpiperazine (a 
piperazine which produces empathogenic and stimulant effects) 
Comedown To lose the effects of a drug and return to a normal or more normal 
state 
Chemsex The use of drugs, often illegal ones, to increase pleasure during sex 
Chems  In the context of chemsex, the use of crystal methamphetamine,  
  mephedrone, and/or GHB/GBL 
DRD  Drug Related Deaths 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
GGC  Greater Glasgow and Clyde 
Headshop A retail outlet selling a range of NPS or „legal highs‟ and other 
paraphernalia used for consumption of drugs such as cannabis 
IEP  Injecting Equipment Provider 
IDU  Injecting Drug User 
MDA  Misuse of Drugs Act 1971 
MSM  Men who have Sex with Men 
NEET  Not in Education, Employment, or Training 
NPS  New (or Novel) Psychoactive Substances 
On tick To buy drugs, usually with the agreement to pay later 
ORT  Opiate Replacement Therapy 
Party pills See BZP 
PSA  Psychoactive Substances Act 2016 
PWID  People/Person Who Inject Drugs 
SALSUS Scottish Schools Adolescent Lifestyle & Substance Use Survey 
SCJS  Scottish Crime and Justice Survey 
SDF  Scottish Drugs Forum 
SDMD Scottish Drug Misuse Database 
Slamming Injecting during chemsex 
TCDO Temporary Class Drug Order  
UNODC United Nations Office on Drugs and Crime 
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Glossary: Drug Wheel Categories 
This report utilises The Drugs Wheel to categorise substances into comparable 
groups. This tool, developed by Mark Adley, was developed in response to the 
rapidly expanding number of psychoactive substances available. More information 
on this tool can be found at www.thedrugswheel.com. A visual presentation of the 
wheel is found within the „Introduction‟ section of this report. The table below 
presents a breakdown of the categories, providing common effects and examples 
for each. 
 
Name Common Effects1 Example(s) 
Cannabinoids 
“Stoned”, calm, munchies, chilled out, floaty, 
giggly, sensual, paranoid, dry mouth, anxiety, 
lazy, mental health issues. 
Cannabis 
Depressants 
“Buzzing”, euphoric, confident, relaxed, risk-
taking, withdrawal, unconsciousness, coma, 
vomiting, death. 
Diazepam, 
GHB/GBL, 
Gabapentin 
Dissociatives 
“Out of body”, euphoric, floaty, disconnected, 
relaxed, numb, scared, unable to move, in a 
“hole”. 
Ketamine, Salvia, 
Methoxetamine 
Empathogens 
“Loved up”, connectedness, warmth, 
understanding, sweating, arousal, mood swings, 
depression. 
MDMA (ecstasy), 
PMA, MDAI 
Opioids 
“Invincible”, confident, pain-free, safe, euphoric, 
constricted pupils, addiction, hallucinations, 
withdrawal, overdose. 
Heroin, Tramadol, 
Morphine 
Psychedelics 
“Trips”, spiritual connection, heightened senses, 
visual or auditory hallucinations, anxiety, panic, 
mental health issues. 
LSD, 5-MeO-DALT, 
AMT 
Stimulants 
“Uppers”, increased energy, increased heart 
rate, euphoria, dilated pupils, paranoia, anxiety, 
sexual arousal, sexual impotence, comedowns. 
Amphetamine, 
Cocaine, 
Mephedrone 
 
 
  
                                         
1
 All common effects taken from Adley (2016) The Drugs Wheel. Available at: 
http://www.thedrugswheel.com/downloads/TheDrugsWheelCategories_2_0.pdf [last accessed: 26/7/2016] 
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Glossary: NPS Categories 
Throughout this report, NPS types will be linked to Drug Wheel categories. The 
table that follows sets out the categories we discuss, the corresponding Drug 
Wheel category, and some commonly used names. 
 
Name Drug Wheel 
Category 
Commonly Used Names 
Synthetic 
Cannabinoids 
Cannabinoid 
Bombay Blue, Annihilation, Clockwork Orange, 
Doctor Green Thumb, Exodus, Herbal Haze, 
Joker, Sensate, Pineapple Express, Spice, 
Herbal Incense 
Benzodiazepine-
type NPS 
Depressant 
Phenazepam, Etizolam, Diclazepam, 
Flubromazolam, Flubromazepam 
Stimulant-type NPS Stimulant 
Gogaine, Ching, Mr. White, Columbiana, Charly 
Sheen, Dust till Dawn, Ivory Wave, Blue Stuff, 
Bath Salts, Sniff 
Mephedrone Stimulant 
Magic, Bubbles, M-Cat, Meow Meow, Plant 
Food 
GHB/GBL Depressant G 
Ethylphenidate Stimulant EP, Burst, Ocean Burst 
Salvia Dissociative Salvia, Sally D 
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Executive Summary 
Background 
New or Novel Psychoactive Substances (NPS) imitate the effects of illegal drugs 
and are commonly (although misleadingly) referred to as „legal highs‟. Over the 
last decade the use of NPS has expanded in Scotland. Current data sources and 
anecdotal reports have identified a number of vulnerable or potentially at risk 
groups. This report presents results of mixed methods research on NPS use 
among five key target populations: vulnerable young people, people in contact 
with mental health services, people affected by homelessness, people who inject 
drugs (PWID) and men who have sex with men (MSM).  
Methods 
Qualitative interviews were undertaken with 33 people who had taken NPS. Over 
half of participants belonged to two or more target groups. Four focus groups were 
run with front line staff working with people who use NPS across Scotland, and 
attended by 42 practitioners. Key themes from qualitative analysis of the 
interviews and focus groups were used to inform the design of two surveys:  one 
for service users2 (the NPS survey), and one for staff (the staff survey). 424 
service users and 184 front line workers completed the surveys.  
Findings 
Findings are presented on patterns of NPS use, motivations for and 
consequences of use, and treatment and legislative responses. 
 
Patterns of NPS Use: Key Findings 
Various service data sets were explored, including specialist drug service data and 
national data sets, in an attempt to derive prevalence estimates within vulnerable 
populations across Scotland, but none were sufficiently robust. 
 
However, local estimates for NPS use among people who inject drugs were 
derived in two parts of Scotland from data from injecting equipment providers. 
From analysis of existing needle exchange data for NHS Greater Glasgow and 
Clyde (GGC) and NHS Lothian, we estimate that there are 190 (confidence 
interval 114-265)3 injecting NPS users in NHS GGC and a further 673 (confidence 
interval 562-784) NPS injectors in the NHS Lothian area.  
 
Use of NPS was widespread in the survey sample with 59% (n=252) of 
                                         
2 Participants for the survey were recruited primarily through services including homeless drop ins. To 
increase reach, participants were also recruited online. The majority of surveys were by clients of services, 
however a small proportion were completed online by individuals not necessarily in contact with services. 
3
 A confidence interval gives an estimated range of values which is likely to include the true value.  
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respondents reporting that they had ever used NPS. Of those, 74% (n=185) 
reported having used NPS within the last six months.  
 
Poly-substance use amongst the sample was very high. Only one person reported 
being a sole NPS user, with 99% (n=251) of NPS users also reporting traditional 
drug use. The most commonly used NPS were synthetic cannabinoids (41%, 
n=104) and benzo-type NPS (41%, n=102), while approximately one fifth reported 
taking stimulant-type NPS (21%, n=53) and mephedrone (19%, n=48).  
 
Preferred route of administration varied by substance. Smoking was most 
common for synthetic cannabinoids (98%, n=91), whereas oral (66%, n=57) and 
sublingual (under the tongue) (28%, n=24) were most common for 
benzodiazepine-type NPS. Stimulant-type NPS were more commonly taken by 
snorting (51%, n=25) or injecting (33%, n=16). 
Motives: Key Findings 
There were a wide range of reasons reported for people using NPS. The key 
motives related to ease of access, curiosity and influence of peers, as well as 
pleasure, price and potency.  Legal status did not appear to be a key motivator for 
use. 
 
Other specific motivations were associated with particular groups of respondents. 
For example MSM were more likely to highlight improving sex as a key motivator 
for use. Those with a history of benzodiazepine use were more likely to highlight 
substitution from prescribed drugs as a key motivator for use.  
 
Reasons for not trying: Reasons for not trying NPS were explored in the 
qualitative interviews only. These generally related to awareness of the harms 
from observing NPS use among their peers. 
 
Reasons for trying: The key reasons for trying NPS related to price, curiosity and 
ease of access, including being offered through peers. 
 
Reasons for stopping: The key reasons for stopping use of NPS reported in the 
study related to „not liking it‟ or in relation to specific harms that individuals had 
experienced, for example having a negative impact on mental or physical health. 
 
Reasons for continuing to use: The reasons for continuing to use NPS 
overlapped with reasons for trying and in particular around ease of access. In 
addition, motives for continuing also related to pleasure and compulsion. More 
functional reasons for continued use related to people using in an attempt to self-
manage underlying mental health problems or dependency and a desire to avoid 
going into withdrawal.  
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Consequences of Use: Key Findings 
The surveys identified multiple harms associated with the consequences of using 
NPS. The negative consequences of use can broadly be described in terms of 
mental and physical health harms and social harms. 
 
Positive effects were identified by some. This was generally when under the 
influence of NPS, and negative after effects were often described. Use of NPS by 
MSM for chemsex saw half of respondents report no negative after effects for 
mental health (n=15/29) or social consequences (n=15/29). Those who reported 
benzodiazepine-type NPS use also identified positive effects on managing sleep 
and mental health, with 91% (n=52) reporting that use helped them sleep and 81% 
(n=47) stating that use reduced their anxiety. 
 
Mental Health harms 
Across all NPS users who had used in last 6 months, 25% (n=47) identified 
anxiety, 12% (n=22) paranoia and 20% (n=38) depression as key mental health 
harms.  There was also a significant impact reported on underlying mental health 
conditions and use of NPS to reduce mental health symptoms. 
 
Physical harms 
A range of physical harms were reported. Physical harms varied because of the 
variations in the type of NPS people were using. The negative impact on sleep 
through NPS use was the most commonly reported physical health harm. Across  
all NPS users who had used in last 6 months 20% (n=37) reported problems with 
sleep. Co-ordination problems were also reported by 20% (n=38) of the sample 
and appeared to be particularly prevalent among those who reported use of 
benzodiazepine-type NPS. Population-specific harms were identified such as 
chemsex harms among MSM, injecting NPS among PWID, and unsupervised 
opiate detoxification among opiate users. 
 
Wider social harms 
 
Financial issues: Money and debt were highlighted as major issues. 60% 
(n=105) of respondents to the NPS survey said they had spent more money than 
they planned to on NPS.  39% (n=89) reported that they borrowed money to pay 
for NPS. 
 
Missed appointments: Missing appointments was reported by 60% (n=104) of 
the overall NPS survey sample and highlighted a potential consequence of NPS 
use that could lead to significant further harms, including potential sanctions by the 
Department of Work and Pensions. 
 
Education and Employment: While this was identified as a significant harm in 
the staff survey, it did not feature highly among the harms reported in the NPS 
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survey. It was however recognised as a greater issue by MSM than for other 
vulnerable populations.  
 
Loss of tenancy: Staff perceived loss of tenancy as a social harm amongst 
people who use NPS (49%, n=90). Although it was reported less frequently in the 
NPS survey approximately 20% (n=35) of those who responded to a question on 
problems caused by NPS use, reported losing a tenancy as a result of NPS use. 
 
NPS use and relationships: The majority of NPS survey respondents reported 
negative effects on their relationships with family following on from NPS use, 
something that was also identified by the staff survey. A quarter (26%, n=45) 
reported struggling with caring commitments. 
 
Treatment and Psychoactive Substances Act: Key Findings 
Contact with services: 36% (n=69) of all NPS users were not in contact with 
drug services at all for any issue4.  Overall contact with services was high, which 
was not surprising given the nature of the population and the fact that a large 
proportion were recruited through services.  However only 11% (n=26) of NPS 
survey respondents reported being in contact with one or more services 
specifically in relation to their NPS use. People in contact with mental health 
services reported the highest level of contact with services regarding their NPS 
use (20%, n=18).  
 
Use of emergency services: While the vast majority of vulnerable people in the 
study chose not to discuss their NPS use specifically with the services they were 
in contact with, there was a higher level of use of emergency services.  32% 
(n=77) had called an ambulance for someone else and 23% (n=55) had an 
ambulance called for them as a result of NPS use. 26% (n=63) of NPS users had 
attended A&E as a result of NPS use. 
 
Provision of information and support: Sources of information on NPS consisted 
primarily of talking to family and friends (32%, n=70).  31% (n=67) had not tried to 
source any information on NPS prior to use.  16% (n=34) had talked to a drug 
service and 16% (n=35) accessed information leaflets. 16% (n=34) had obtained 
information on NPS from TV documentaries. 
 
This low uptake of obtaining information from services was explained by a 
perception among those surveyed that in general workers knew little about NPS. 
This perception was borne out by services who felt that it was hard to „keep up to 
date‟.  
 
                                         
4
 Not all respondents answered each question. Where answers are missing these have been excluded 
from the analysis so figures that describe the same population may have different base sizes 
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Providing support - client disclosure of NPS use: Only a small proportion of 
those surveyed said they had discussed their NPS use with services. This 
contrasted with services, with 75% (n=131) of staff reporting that they ask service 
users about NPS use at first presentation. This suggests that there is considerable 
under-reporting of NPS, making effective engagement by services challenging. 
Qualitative focus group feedback suggested that how questions about NPS use 
are asked can affect disclosure of use from clients. 
 
Client service relationship: The qualitative interviews and focus groups 
suggested that improving the provision of credible information and building trust 
were key to improving disclosure and enabling services to respond more 
effectively.  
 
Improving services: There were a range of views on what service developments 
were required from respondents to the NPS survey. Those who had used NPS 
were asked what one option was the most important service to offer. Responses 
included: 
 
 Detox/rehab (27%, n=66) 
 Specialist services for NPS (15%, n=38) 
 Information provision (13%, n=33) 
 Specialists within services (13%, n=31)  
 
Service providers identified some similar themes on what they would like to offer in 
the staff survey, particularly the development of local specialist services for NPS 
(47%, n=87), specialists within a service (45%, n=82) and information leaflets 
(40%, n=73). 
 
The Psychoactive Substances Act (PSA): The Act came into force after most of 
the survey work had been completed and therefore findings are largely focused on 
the likely impact. 57% (n=141) of those surveyed felt it would have no impact, this 
being highest among MSM with 74% (n=28) of this group believing it would have 
no impact on their NPS use. Over a quarter (29%, n=73) of all respondents to the 
NPS survey said they would move or return to traditional drugs. 
 
45% (n=112) of the NPS survey sample said they bought NPS from shops and 
clearly this will have changed following the closure of „head shops‟. Staff 
anticipated a shift to online buying to a greater extent than those who reported 
using NPS. 
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Key Learning Points 
Prevalence estimates of NPS use among vulnerable populations 
1. Database tools such as DAISy should be adapted and in the case of needle 
exchange data collection, standardised, to include specific questions relating to 
NPS use, this may include individual NPS names or categories.  Training for 
frontline workers in how best to apply these tools should be incorporated in this 
process. 
In order to develop more robust estimates of NPS use there needs to be an 
improvement in data collection within services.  The new database for drug and 
alcohol services currently being developed (Drug and Alcohol Information System 
– DAISy) provides an opportunity to collect reliable data provided staff are enabled 
to undertake thorough initial assessments and adequately record these.  Similarly 
needle exchange data has the potential to provide useful prevalence data, again 
provided staff are appropriately equipped to encourage accurate disclosure of 
NPS use. 
Motives for use 
2. Motives for use should be identified in assessments and reviews with service 
users and used to inform care plans undertaken by support services and 
frontline staff. 
A better understanding of motives for NPS use and the ways they vary by 
population group and type of NPS can inform interventions by services. In 
particular there may be benefits of targeted interventions for people who intend to 
continue using, reduce use, or want to stop. 
Consequences of use 
3. Mental health harms: Greater partnership working between substance use 
and mental health services and a review of care pathways for those with 
substance use and mental health difficulties should be considered. 
Given the reported mental health impacts of NPS use better collaboration and 
partnership working between mental health services and drug services may help 
to improve care for this population.  A review of care pathways for those with 
substance use and mental health difficulties would assist in improving the 
treatment response for service users. Further research would also help to better 
understand the complex effects of NPS use on mental health, both in relation to 
specific substances and mental health conditions. 
4. Physical harms: Assessments within key services should cover a range of 
physical health areas including sleep management. 
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The most common reported physical harm across the majority of NPS types was 
sleep problems. Dedicated resources or information on sleep management could 
be useful to explore. Taking account of the range of other physical harms reported 
and given the low levels of reported disclosure of NPS use, assessments within 
key services which cover a range of health areas could assist in opening up a 
dialogue regarding NPS use and related harms.  Such assessments may also 
encourage better disclosure of NPS use.  
 
5. Social harms: Multi-agency and flexible working approaches such as assertive 
outreach should be continued and developed to support people with the range 
of social harms experienced. 
 
NPS use had a significant impact on a range of aspects related to the ability to 
cope with daily living including finance, maintaining appointments and tenancies.  
NPS use can result in the most vulnerable populations experiencing significant 
harm, which puts them at great risk. Approaches should be explored which protect 
such vulnerable individuals and highlight the need for multi-agency and flexible 
working to support people with a range of different issues.  
 
Improving practice 
6. Frontline services should consider providing basic NPS training for all staff, as 
well as training in a variety of health based topics and assessment for support 
staff.  
The lack of expertise and ability to keep up to date with knowledge on NPS within 
services was reported by both NPS users and staff.  In relation to workforce 
development, a minimum requirement in terms of improving practice is the 
provision of basic NPS training for all staff. Linked to this would be the provision of 
at least annual updates on new NPS trends. Training in a variety of health based 
topics and assessment would also assist in being able to identify NPS use and 
harms. 
 
Service Developments 
7. Health board and ADP areas should review possibilities for service 
developments or adaptations to existing services to respond to those who use 
NPS. 
 
Specialist treatment for NPS including detox was identified as important for staff 
and service users alike.  Development and expansion of the remit of established 
treatment services including use of specialist workers could be explored to meet 
this need.  Services should explore how they might adapt to attract less traditional 
client populations who use NPS. This could include exploring specific clinics, 
opening outwith standard hours and changing service branding.  Services should 
also consider developing the skills and expertise of one member of staff who can 
keep up to date with new developments and provide advice and assistance to 
other staff.  
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Vulnerable populations 
8. Multi agency and targeted responses should be explored for the different 
populations using NPS. 
There was considerable cross over between the target populations of this study, 
although MSM and vulnerable young people were largely separate groups.  Multi-
agency responses are required for those groups experiencing multiple 
disadvantages.  There is a need for specific service developments within key 
services that MSM are likely to use, for example, sexual health services and 
targeted MSM health provision where it exists.  Similarly services for vulnerable 
young people should explore how best to address NPS and wider substance use 
among their young people. 
 
Information on NPS to users 
9. Information resources in a variety of formats are required to reach the different 
populations who use NPS. 
The lack of access to information sources on NPS was evident.  Reliable and 
credible sources of information on NPS need to be developed which can be made 
accessible to those from vulnerable populations who use NPS.  
 
Psychoactive Substances Act 
10. Monitoring of the impact of the Psychoactive Substances Act (PSA) on 
vulnerable populations should be undertaken by ADPs, health boards and 
services with a particular focus on increased overdose risk. 
There were a range of views on the potential impact of the new legislation but no 
real clarity on its likely impact. It will be important to track the impact of the PSA 
particularly in relation to changes in supply routes that might have specific effects 
on vulnerable populations who use NPS.  For example there may be increased 
risk of overdose for opioid users who also use NPS, who return to opioid use and 
may have reduced tolerance. Alcohol and Drug Partnerships and Naloxone 
coordinators should be alerted to the potential for increased overdose risk so that 
appropriate action can be taken, including supply of Naloxone to vulnerable 
populations. 
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1. Introduction 
1.1  Background to the Study 
New (or Novel) Psychoactive Substances (NPS) are a category of substances, 
either manufactured or plant based, which seek to imitate the effects of illegal 
drugs5. These substances are commonly, although misleadingly, referred to as 
„legal highs‟.  
Globally, in recent years the number of NPS being reported has grown 
exponentially. Since 2008, 644 NPS have been reported to the United Nations 
Office on Drugs and Crime (UNODC) Early Warning Advisory on NPS.  This has 
included a widening of the the profile of substances being reported to include new 
groups of substances6. Notifications to the EU Early Warning System have also 
risen rapidly, from 14 in 2005 to 98 in 20157.  
Often, newly reported NPS are derivatives of previously reported substances with 
a slightly modified molecular structure8. This has resulted in a rapidly changing 
drug use landscape9 with some NPSs remaining on the market for a long time 
(such as mephedrone and other cathinones) with others only being reported briefly 
before disappearing from the market10.  
Prevalence of NPS use in Scotland from traditional drug prevalence estimates 
such as the Scottish Crime and Justice Survey (SCJS), and Scottish Schools 
Adolescent Lifestyle and Substance Use Survey (SALSUS) suggests that use 
amongst the general population is low. SCJS found just under 2% of adults 
reported that they had taken any NPS (powders, pills, herbal mixtures or crystals 
that are sold as „legal highs‟), at some point in their lives.  Use of NPS was higher 
amongst younger age groups, with 4% of 16-24 year-olds reporting having ever 
used „legal highs‟11. The 2015 SALSUS survey highlighted that 13% of 15 year 
olds had ever been offered NPS. However, a lower proportion reported use: 
approximately 5% of 15 year olds reported ever using one or more NPS, and of 
these, 2% reported having taken at least one NPS in the last month12.  
However, there are limitations associated with these estimates. SALSUS is a 
school-based survey, and the SCJS is an opt-in household survey. This means 
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 UNODC (2013) The Challenges of New Psychoactive Substances. 
6
 EMCDDA (2015) NPS in Europe An update from the EU Early Warning System March 2015 
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 EMCDDA (2016) Health Responses to New Psychoactive Substances. 
8
 UNODC (2016) World Drug Report. 
9
 Wyckmans et al (2015) „Novel Psychoactive Substances: a worldwide problem that requires an adequate 
approach‟. 
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 Seddon (2014) „Drug policy and global regulatory capitalism: The case of new psychoactive substances 
(NPS)‟. 
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 SCJS (2016) Scottish Crime and Justice Survey 2014/15: Drug Use.  
12
 SALSUS (2016) Drug use Report 2015 
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that they are unlikely to capture young people who may be absent, truant or 
excluded from school, and the marginally housed13,14.  
There is also a need to better understand the harms associated with NPS use. 
Over the last few years, Scottish statistics on Drug Related Deaths (DRD)15 have 
shown a significant increase in the recording of NPS present at time of death, 
rising from four deaths in 2009 to 112 deaths in 2015. The profile of NPS-related 
deaths follows a fairly typical pattern to other DRDs in Scotland, with those 
experiencing fatalities being on the whole from vulnerable populations. In 
addition, poly-drug use is common, and in the majority of cases, traditional drugs 
either play a key role in that death, or remain the main cause of death.   
From the NRS DRD figures in 2015, NPS were implicated in 74 deaths, with 3 
where NPS were the only substance present.  The most commonly implicated 
NPS in these 74 deaths were benzodiazepine-type NPS such as phenazepam, 
etizolam, and diclazepam16.  
1.2 The Legal Context of NPS in Scotland  
The Psychoactive Substances Act 2016 (PSA)17 makes it an offence to produce, 
supply or offer to supply any psychoactive substance if the substance is likely to 
be used for its psychoactive effects, regardless of its potential for harm. The only 
exemptions from the Act are those substances already controlled by the Misuse of 
Drugs Act 1971 (MDA), and nicotine, alcohol, caffeine, medicinal products and 
specified foodstuffs.  
Prior to the PSA coming into force, the two key legal instruments which affected 
the production, supply, and possession of NPS in the UK were the Misuse of 
Drugs Act (MDA) 1971 and Temporary Class Drug Orders (TCDOs) 2011. 
1.3 Aims and Objectives of the Study  
In 2014, the Scottish Government established a programme of analytic work to 
develop the evidence base on NPS, including establishing a deeper understanding 
of the motives for, and harms of NPS use. Following the Scottish Government‟s 
evidence review18 and suggestions from the NPS Evidence Group, it was 
proposed19 that research into the motives, prevalence, and harms of NPS-use 
amongst vulnerable or potentially at risk populations was conducted. The Scottish 
Government commissioned this research in June 2015, in order to address the 
gap in current published work on NPS in Scotland. 
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 SALSUS (2016) Technical Report 2015. 
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 SCJS (2016) Scottish Crime and Justice Survey 2014/15: Drug Use 
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 NRS Scotland (2016) Drug Related Deaths in Scotland - 2015. 
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 Ibid 
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 The PSA came into force on the 26
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 May 2016, which fell during the quantitative survey phase of data 
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 April to 10th June 2016). 
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 Fraser (2014) New Psychoactive Substances – Evidence Review. 
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 Gillies, A. (2015) Closing the Evidence Gaps on the Prevalence and Harms of New Psychoactive 
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The aim of this study is to provide data on the patterns of use, motivations for and 
harms of NPS use  amongst the following groups: 
 Vulnerable young people, including:  
o looked after and accommodated children  
o care leavers 
o young homeless  
o those not in education, employment, or training (NEETs) 
 People in contact with or identified by mental health services  
 People affected by homelessness 
 People who inject drugs (PWID)   
 Men who have sex with men  (MSM) 
 
The research questions driving this project were as follows: 
i. What is the prevalence of use of different categories of NPS amongst 
target populations in Scotland?  
ii. What are the stated motivations for experimenting with and 
continued use of NPS among target populations in Scotland?  
iii. How are the harms associated with the use of NPS understood by 
those who use them and those who provide specialist services to 
target populations in Scotland? 
1.4 Study Population 
In recent years, there has been much public debate about NPS use in Scotland. 
There is limited evidence on prevalence of use in Scotland, however anecdotal 
information has been reported to national drug agencies, and drug monitoring 
groups in Scotland. Early concerns were raised by frontline services, including 
Accident and Emergency departments who were identifying acute NPS 
intoxication, and mental health services who were reporting both new and existing 
patients with significant issues potentially linked to NPS use. From as early as 
2009, enquiries about NPS were being made to national drug support and 
information agencies, including Scottish Drugs Forum. It was established through 
information and training requests that NPS use was an emerging issue faced by 
homelessness services, and services for looked after and accommodated children 
and vulnerable young people. The use of NPS in these settings proved to be a 
significant issue for staff in terms of management of people who use NPS, but also 
in terms of the harms that people who use NPS were experiencing. 
 
More recently, there have been concerns about use among existing intravenous 
drug users, particularly injectors in Edinburgh and Lothian who were experiencing 
injecting-related injuries as a consequence of ethylphenidate injecting. In some 
cases this included outbreaks of serious bacterial infections20. There have also 
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 Lafferty et al (2016) „The Experience of an Increase in the Injection of Ethylphenidate in Lothian, April 
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been ongoing concerns about substance use, and particularly NPS use in MSM 
who are engaging in drug use for the purpose of enhancing sex, known as  
„chemsex‟. The extent and nature of „chemsex‟ in Scotland has been the subject of 
much discussion21. However, while specialist services have developed in England, 
Scotland has struggled to identify any patterns in reported use, and developing 
appropriate responses has been hampered by a lack of data.   
There has also been evidence of NPS use in acute mental health services, with 
NPS use identified in over a fifth of admissions in Edinburgh inpatient wards22.  
It is worth noting that some of the patterns of use observed elsewhere in the UK 
and in Ireland have not been reported in Scotland.  For example there was 
evidence of stimulant injecting reported in Ireland23 when there seemed to be very 
little of this pattern of use being observed or reported in Scotland. The question of 
whether such behaviours were being missed or whether they could be predicted to 
develop is partly answered in this report. 
This research is focused on the five vulnerable groups described above. These 
groups have been selected for two reasons. Firstly, the emerging picture suggests 
there are distinctive issues amongst these groups where problem use is a 
significant feature. Secondly, an improved understanding of use in these groups 
can contribute to an improved response to NPS use in Scotland. 
1.5  Defining NPS 
Various definitions for NPS exist and at the time of data collection for this 
research, there was no legal definition. However, the Psychoactive Substances 
Act, which came into effect on 26th May 2016, defined Psychoactive Substances 
as:  
“Any substance which is capable of producing a psychoactive effect in a 
person who consumes it, and is not an exempted substance [i.e. alcohol, 
tobacco, medicines and controlled drugs, caffeine and foodstuffs such as 
nutmeg and chocolate]…A substance produces a psychoactive effect in a 
person if, by stimulating or depressing the person‟s central nervous system, 
it affects the person‟s mental functioning or emotional state… A person 
consumes a substance if the person causes or allows the substance, or 
fumes given off by the substance, to enter the person‟s body in any way.”24 
 
In this study, the approach taken was to work with, and use, participants‟ own 
understandings of what constitutes NPS, or as participants commonly called them, 
legal highs or „legals‟. They did not always distinguish NPS from 'traditional' drugs, 
and often did not know about, or in some cases care about, the legal status of a 
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 Stanley et al (2016) „Use of Novel Psychoactive Substances by Inpatients on General Adult Psychiatric 
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 Van Hout, M.C. and Bingham, T. (2012) „A costly turn on: patterns of use and perceived consequences 
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given substance. As a result, the analysis presented here follows the participants‟ 
understandings of NPS, regardless of their legal status at the time of writing, data 
collection or event recalled.  
Unlicensed benzodiazepines: Of particular note is one substance group which 
differs in some ways from other NPS. Anecdotal evidence from services 
suggested high rates of unlicensed benzodiazipine use. „Unlicensed 
benzodiazepines‟ refer to benzodiazepines classified as medicines in other 
countries in Europe and elsewhere, but not licensed for medical use in the UK. 
These include substances such as Phenazepam, Etizolam and Dicalzepam. Their 
comparatively recent availability in Scotland, the fact that they have been sold in 
shops and online and their inclusion as NPS in DRD figures in Scotland coupled 
with anecdotal evidence from services has led to their inclusion as NPS for 
analysis within this study. For the purposes of this report we will refer to them as 
benzodiazipine-type NPS. 
Chems: A final point to note is the use of the term „chems‟ in the gay community 
and amongst MSM more widely. „Chems‟ is an all-encompassing term which can 
include both NPS and what might be described as more traditional drugs. Where 
specific drugs are named in definitions of chemsex, these tend to be crystal 
methamphetamine, mephedrone and GHB/GBL. Amongst MSM, the term G is 
used to refer to both GHB and GBL, thus the term „G‟ or GHB/GBL will be used.  
Categorising NPS 
In February 2016, the Scottish Government published the results of a stakeholder 
consultation on defining NPS25. This found a strong consensus for utilising the 
Drugs Wheel model [Fig.1, below] to classify psychoactive substances.  
Therefore, within the broad definition described above, substances were 
categorised according to their effects. The Drugs Wheel categorises both 
traditional and NPS substances in this way. This approach is useful for this 
research because it reflects the way that users commonly categorise the 
substances they take – i.e. that they are like another substance with a similar 
effect - rather than being concerned with other possible categorisations – legal 
status or route of administration, for example.   
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Fig 1.1 Adley (2016) The Drugs Wheel [www.drugswheel.com] 
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2. Methods 
This mixed-methods research was carried out between December 2015 and July 
2016. Qualitative interviews and focus groups were used to identify key themes 
and concerns about motives and consequences of NPS use.  This informed the 
design of two surveys, one exploring issues with those who use NPS in Scotland, 
and another aimed at staff working in services, where they may encounter people 
who have taken NPS. Models to estimate prevalence were explored using the 
survey data, data from the Scottish Drug Misuse Database (SDMD) and the 
analysis of needle exchange data from existing Neo360 data sets for Glasgow and 
Lothian. 
2.1  Ethics and Research Governance Permissions 
Ethical approval for this project was given by the NHS West of Scotland Research 
Ethics Committee (15/WS/2010). Research and Development (R&D) approval was 
granted for all 14 territorial health boards except Forth Valley for qualitative data 
collection, and all 14 territorial health boards for survey data collection. 
Pseudonyms have been used throughout for interview participants.  
2.2  Prevalence Estimates 
When attempting to quantify the number of people in a population that use drugs 
we have recourse to a number of different methods.26 Traditionally, surveys based 
on random sampling have been used to give information on the extent of drug use 
among the general population, for example the Scottish Crime and Justice Survey 
(SCJS). However there are limitations to this approach, particularly when trying to 
assess patterns of drug use amongst vulnerable populations.  
Other approaches to estimate „hidden‟ groups that may not be picked up in survey 
data (such as capture-recapture) have been used in Scotland to estimate national 
and local prevalence of problem opioid and benzodiazepine use. This approach 
uses multiple data sources to estimate the size of the hidden population of 
problem opioid and benzodiazepines users27, although estimates to date do not 
include problematic use of other substances such as cocaine. There are several 
challenges posed in estimating NPS use in this way. Recording of data on NPS 
within existing routine datasets is currently limited28. This is the case not just within 
Scotland, but across Europe and internationally, where the systematic collection of 
data on NPS in healthcare settings is scarce29. This means that sufficient numbers 
of NPS users do not appear in existing data sources to make a multi-source 
method such as capture-recapture viable.  
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In light of these challenges, the approach adopted for this study was to explore the 
multiplier method. We also estimated the number of injecting NPS users in two 
NHS areas: NHS Greater Glasgow & Clyde and NHS Lothian.  
 
2.2.1 Multiplier Method 
The multiplier method is a simple way of estimating unknown populations such as 
prevalence of drug use. The method uses the available information on the 
population in question as a benchmark, e.g. number of drug users in treatment, 
and applies a multiplier that is related to the population and has normally been 
derived from a small-scale study.  For this study, this method involved using the 
number of NPS users from our quantitative „NPS survey‟ who reported contact 
with drug treatment services. From this a multiplier was calculated and used in 
combination with the numbers of NPS users in treatment from the Scottish Drug 
Misuse Database (SDMD). This provides data on the total number of people in 
Scotland who presented for initial assessment at drug treatment services.  
The construction of the treatment multiplier used the 125 NPS users identified in 
the quantitative survey  in contact with drug treatment services. 194 NPS survey 
participants answered this question giving a treatment rate of 64%. This was then 
used in combination with data from ISD on treatment numbers for 2014/15 to 
produce an estimate.   
However, this estimate was not considered to provide a sufficiently robust 
prevalence figure for NPS use in this population. The analysis demonstrated 
that data sets were not sufficiently complete and too many assumptions had to be 
made. One major limitation of the SDMD data is it collects data on new treatment 
episodes and there is very limited follow up data available. In addition, the data 
from SDMD referred to both Mephedrone and „other‟ drug users. It is unclear what 
drugs this „other‟ category includes and it may not be mainly other NPS users. 
This adds to the uncertainty around the estimate and impacts on its robustness. 
More details on the calculation are provided in Appendix B. 
2.2.2 Estimating the prevalence of injecting NPS takers using NEO data 
For this estimation, data from pharmacies/needle exchange services in both areas 
were used and an estimate of the hidden population was made by examining the 
frequency of visits to the needle exchange by NPS injectors. Further information 
on the methods applied can be found in the technical report (see Appendix A). 
2.3 Qualitative data  
Qualitative data were collected from interviews with people who have taken NPS, 
as well as from focus groups with staff working in services likely to come into 
contact with NPS users.  
Purposive sampling was used in recruitment for both interviews and focus groups 
as the aim of the qualitative component of the research was not to create a 
representative sample of people who had taken or worked with people who have 
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taken NPS, but to ensure a diverse range of views to enhance the understanding 
of NPS use amongst vulnerable groups.  
2.3.1 Interviews: Recruitment and Sampling 
Purposive sampling was used to recruit 33 people who had taken NPS (self-
defined) for interviews, including participants from both urban and rural areas, and 
men and women. In addition, participants were purposively recruited from the 
following groups: 
 Vulnerable young people (aged 16-24)30 
 People in contact with mental health services (formerly or currently in 
contact) 
 People who inject drugs (PWID) 
 Adult homeless people (current or formerly homeless) 
 Men who have sex with men (MSM) 
Participants were recruited for interview by circulating information to managers, 
lead contacts in Alcohol and Drug Partnerships (ADPs), Managed Care Networks 
(MCN), statutory and third sector settings, and across all Scottish health boards 
except NHS Forth Valley31. Potential participants were invited to make contact with 
a researcher by posters placed in service waiting rooms or where appropriate by 
being given the information by their key worker.  Researchers also attended drop-
in services where people were offered the opportunity to opt in to the study directly 
through the researcher who attended on the day. See Appendix C for a full list of 
interview participants. 
2.3.2 Interviews: Data Collection 
In-depth interviews were undertaken with 33 people who identified themselves as 
having taken NPS, from nine Scottish Health Boards. Around two thirds of 
participants were recruited from Ayrshire and Arran, Greater Glasgow and Clyde 
and Lothian, with smaller numbers from Dumfries and Galloway, Fife, Grampian, 
Highlands, Lanarkshire, and Tayside.  
In line with findings from current research on people with drug dependencies32, 
almost half (48%) of interviewees belonged to two or more of the target groups. 
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For example, many injecting drug users were also in contact with mental health 
services. 
20 (61%) participants were men, and 13 (39%) participants were women. As one 
of the target groups was MSM, this increased the size of the male sample. The 
mean age was 32 (range: 16-61).  
Of the total, 20 (61%) reported they no longer took NPS at the time of interview. 
No participant reported having taken NPS only. That is, all reported having, at 
some time, taken illegal or more traditional drugs.    
Interviews addressed circumstances of NPS use initiation, NPS knowledge and 
what they perceived to be positive and negative effects and consequences. 
Sources of support in relation to first use of NPS and most recent use of NPS 
were also addressed (see Appendix D for topic guides). Interviews lasted on 
average 45 minutes, and participants were given a £10 high street voucher to 
thank them for their contribution. 
2.3.3 Focus Groups: Recruitment and Sampling 
Purposive sampling was used to recruit 42 staff working with clients who use NPS, 
including participants from both urban and rural areas, drug and non-drug services 
(e.g. sexual and mental health services). Four focus groups were undertaken in 
NHS Lothian, NHS Greater Glasgow and Clyde, NHS Highland, and NHS 
Grampian, with front line workers from across these and other areas. Focus group 
participants were purposively sampled for geographical range and type of service 
represented. A full breakdown of regional information for focus group participants 
can be found in Appendix E. 
Focus group participants were recruited by asking managers and lead contacts at 
ADPs, NHS, Social Work and third sector organisations to cascade an email 
invitation to front line workers. It was also cascaded through Scottish Drugs Forum 
membership list and advertised on national bulletins, newsletters and via social 
media. The study was advertised across Scotland in NHS, statutory and third 
sector settings, and across all Scottish health boards, excluding NHS Forth Valley. 
2.3.4 Focus Groups: Data Collection  
42 statutory and third sector service practitioners contributed to the focus group 
discussions. Almost half of participants were from drug services, with small 
numbers from vulnerable young people's services, needle exchange, mental 
health, sexual health, criminal justice, housing and homelessness and social work 
services. Some services catered to more than one group. The breakdown is 
described in table 2.1 overleaf. 
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Table 2.1 Focus group participants (service practitioners) and service type 
 
Service Type N 
Drugs 20 
Vulnerable young people 7 
Needle exchange 6 
Mental health 6 
Sexual health 6 
Criminal justice 6 
Housing and homelessness 5 
Social work 4 
 
Focus groups lasted, on average, for 90 minutes. Focus group discussion covered 
participants‟ estimates of prevalence and trends, their understandings of why their 
clients take NPS and what distinguishes them from clients who do not, and the 
consequences of NPS use. 
2.3.5 Analysis of qualitative data  
All interviews and focus groups were transcribed verbatim, anonymised, and 
analysed using the qualitative analysis software Quirkos to generate themes within 
the three key areas: prevalence, motives and harms. Additional themes around 
service provision and the then-forthcoming Psychoactive Substance Act were also 
coded. These themes formed the basis of closed option responses in the survey, 
but were also separately analysed thematically for the qualitative analysis.33 
2.4 Quantitative Data  
Quantitative data were collected from two surveys. The first survey sought to 
explore NPS use in Scotland, specifically amongst the vulnerable populations 
listed in section 2.3.1 (the „NPS survey‟). The second survey gathered data from 
staff within services („the „Staff survey‟). Over two thirds of staff survey 
respondents worked in services that provided drug and alcohol support, and 
around one third worked in services that provided mental health services or 
housing and homelessness services.  
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2.4.1 NPS Survey: Recruitment and Sampling 
Two sampling strategies were used to recruit 545 participants within the five 
groups of interest. The first combined purposive sampling of drug and alcohol 
services for geographical range and urban and rural characteristics with 
convenience sampling (whereby everyone who entered the waiting room was 
approached to participate in the survey during data collection). In a small number 
of cases, it was preferred that that workers would bring clients to researchers in a 
separate space. Face to face surveys happened primarily in drug services, 
homeless drop-ins, needle exchange sites, and in some areas mental health 
wards and vulnerable young people's services. Overall, uptake in vulnerable 
young people's services was limited compared to other target groups. Services 
which had large drop-ins or waiting rooms were the most effective in terms of 
recruitment. As there were larger numbers of people attending, researchers could 
directly approach people using the drop in or who were waiting for appointments.  
A substantial number of approached services were unable to facilitate survey data 
collection due to short timescales, workload considerations, participation in Care 
Commission inspections, and perceived lack of interest from service users. 
The second sampling strategy was targeted recruitment for hard-to-access groups 
such as MSM and people in rural areas where it was not possible to recruit by 
attending services in person e.g. in parts of the Highlands and Islands.  This 
involved promotion of the survey online with additional targeted recruitment of 
MSM which took place through a peer researcher recruiting in gay bars, and via a 
banner advert on Grindr, an online dating „app‟ used by MSM. The online version 
of the survey was promoted through the SDF news bulletin, through Facebook and 
Twitter accounts, and was also promoted by many key stakeholders on social 
media. This dual-approach strategy was selected to ensure wide coverage of 
target groups across Scotland.  
2.4.2 NPS Survey: Data Collection 
The survey was developed as an online survey, compatible with administration via 
a handheld tablet computer so it could be administered offline with support of a 
researcher.  Peer researchers received information about NPS, and training in 
administering surveys, from SDF and the University of Glasgow prior to data 
collection. Where requested by services, a project team member supported clients 
in completing the survey in place of peer researchers.  
The survey explored last 6 month drug use, including alcohol, NPS and „traditional‟ 
drugs, and focused on motives and health consequences of use for NPS 
categories in terms of the seven drugs wheel categories34. In addition to this, 
based on findings from qualitative stage, mephedrone (commonly understood by 
interview participants to be NPS despite having been controlled since 2010), 
ethylphenidate (understood by some, particularly homeless, interview participants 
to be NPS), GHB/GBL (commonly used in chemsex), salvia divinorum, and 
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 For more information on The Drugs Wheel, please see the Glossary at the start of this document, or visit 
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benzodiazepine-type NPS were also explored. Finally, participants were asked 
about relationships and social harms in relation to their  NPS use overall. Their 
views on services and on the then-forthcoming Psychoactive Substances Act were 
also sought. 
Ten SDF peer researchers35 administered the survey, helping and supporting 
service users to fill it in using a tablet. This ensured literacy was not a barrier to 
participation and that someone was able to brief people on the survey. It also 
ensured participants‟ consent, gave the opportunity to answer any questions about 
the study, and allowed for signposting to additional support where necessary. Peer 
researchers approached people in service waiting areas.  
All participants in this survey were invited to provide contact details (recorded and 
stored separately from their survey responses) if they wished to be entered into a 
draw for a £100 high street voucher.  
A total of 545 individuals were recruited to the NPS survey, which was completed 
by 424 participants (although not all participants responded to all questions). 59% 
(n=251) were recruited in treatment or service settings and 41% (n=173) online.36 
The largest group represented were people who inject drugs (PWID), totalling one 
third of all survey responses. There was significant overlap between the „risk‟ 
groups which increased the size of the PWID sample. Vulnerable young people 
were the least represented in the sample, at 16%.  
Table 2.2 overleaf presents an overview of the composition of the sample 
according to the target populations, and a breakdown by risk group of the 59% 
(n=252) of respondents who reported ever using NPS.  
  
                                         
35
 Researchers recruited by SDF who have past lived experience of drug use and were formerly or 
currently representative of the research target group, MSM, PWID, in contact with mental health services, 
homeless.  Due to ethical agreements, vulnerable young people were not recruited as researchers and at 
request of services, staff researchers were used for vulnerable young person recruitment. 
36
 Participants for the survey were recruited primarily through services including homeless drop ins. To 
increase reach, participants were also recruited online. The majority of surveys were by clients of services, 
however a small proportion were completed online by individuals not necessarily in contact with services. 
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Table 2.2: Composition of respondents to NPS survey, by ‘risk’ group
37
 
 All respondents NPS users 
Group N % N % 
PWID 141 33 136 54 
Mental health service users 99 23 94 37 
Homeless 92 22 76 30 
Vulnerable young people 69 16 39 16 
MSM 70 17 38 15 
 
The survey respondents fell into a number of „risk‟ group categories and 
highlighted the common issue that vulnerable populations often present with 
multiple issues and treatment needs. We tested whether contact with mental 
health services was independent of homelessness status, and of injecting status, 
and found that those accessing mental health services were at a greater risk of 
being homeless38, and of being PWID39, than those not accessing mental health 
services. Similarly, we tested whether homelessness status was associated with 
injecting status, and found that those who were homeless were more likely to be 
PWID40 than those who were not homeless. 
Respondents had a mean age of 36.7 (range 16-66). NPS users were slightly 
younger than the rest of the sample (average age of 35, compared to average age 
of 39). The overall sample was two thirds (66%) male, 73% male for NPS users. 
This is consistent with existing research that people who have used NPS tend to 
be younger, and tend to be predominantly male41. 
Figure 2.1. gives the breakdown of all drug use from the whole sample who 
completed the survey n=424.  
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Fig. 2.1 Reported drug use by survey respondents 
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2.4.3 Staff Survey: Recruitment and Sampling 
The survey was developed as an online survey and checked it was accessible 
from different NHS and council systems. Managers of NHS, statutory and 
voluntary sector services across all 14 Scottish Health Boards were contacted 
regarding the staff survey, and asked to cascade an invitation email and link to the 
survey web URL to front line workers.  
2.4.4 Staff Survey: Data Collection 
Staff surveys were completed by 184 respondents within 13 Health Boards. Table 
2.3 below presents the breakdown of services offered by the organisation which 
staff respondents come from. Staff respondents often worked in organisations 
where more than one service type was offered. 70% of respondents worked in 
drug and alcohol services, and around one third in mental health services or in 
housing support. Please note, as some workers offer services across two or more 
of these categories, these percentages will not total 100. 
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Table 2.3: Services provided by organisations of staff survey respondents 
Service Type N % 
Drug & alcohol support 128 70 
Mental health services 61 33 
Housing and homelessness support 56 30 
Sexual health services 44 24 
Needle exchange 39 21 
Specialist support services
42
 13 7 
Other 41 22 
 
Table 2.4 presents a breakdown of the client groups that staff respondents work 
with. Due to the services provided, service providers tended to encounter several 
different types of client groups. Four-fifths of staff worked with people with mental 
health issues, and over 70% worked with homeless clients or injecting drug users. 
Table 2.4 Client groups that staff survey respondents work with 
Client Group N % 
People with mental health issues 154 84 
Homeless people 136 74 
People who inject drugs (PWID) 132 72 
Vulnerable young people 82 45 
Men who have sex with men (MSM) 56 30 
I do not work with any of these groups 2 1 
 
2.4.5 Analysis of survey data 
The survey data were analysed using SPSS (IBM SPSS Statistics 22). The 
descriptive analysis of the sample was carried out using frequency tables and 
cross tabulations with chi-squared tests performed to ascertain statistical 
significance. Where differences are statistically significant, this is reported in the 
text.  
                                         
42
 e.g. for women, BME communities, LGBTQI+ groups. 
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As previously stated, there were 424 respondents to the NPS survey, and 184 
respondents to the staff survey. Not all participants completed all questions, and 
thus the data presented within this report should be interpreted in light of this. 
It was also found that respondents who were a young person or an MSM were 
less likely to overlap with the other three „risk‟ groups. In particular, vulnerable 
young people were less likely to also be a PWID, and MSM were less likely to be 
homeless.  
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3. NPS Use among vulnerable populations in 
Scotland 
As described in the Methods chapter, we explored the use of the multiplier method 
(using a treatment multiplier) to estimate the prevalence of NPS use amongst 
vulnerable groups in Scotland. This analysis concluded that it is not currently 
possible to generate a reliable estimate of overall prevalence.  
 
As a result, this chapter focuses on estimates for one of the key target groups 
(injecting drug users), where data from the NEO 360 database were more robust. 
It also describes patterns of NPS use amongst each of the key groups, based on 
responses to the NPS survey, and presents the perceptions of staff in services 
about prevalence of NPS use amongst their clients, based on responses to the 
staff survey.  
3.1  Quantitative survey and ‘risk’ groups 
3.1.1 NPS and other drug use amongst NPS survey respondents 
As described above, the NPS survey was completed by 424 people, 59% (n=251) 
in treatment or service settings and 41% (n=173) online.43 
 59% (n=252) of respondents reported having ever taken NPS. 74% 
(n=184) of those who had taken NPS reported use in the last six months.  
 The majority of those using NPS in the last six months reported having 
taken synthetic cannabinoids (41%, n=104) and benzo-type NPS 
(41%, n=102), while approximately one fifth reported taking stimulant-
type NPS (21%, n=53) and mephedrone (19%, n=48).  
 Poly-substance use was very high. Only one person reported being a 
sole NPS user, with 99% (n=251) of NPS users also reporting traditional 
drug use. 
 86% (n=364) of all respondents to the NPS survey reported ever using 
traditional illicit drugs. Use of illicit substances within the last 6 months 
included: cannabis (40%, n=148), benzodiazepines (29%, n=105), heroin 
(23%, n=83) and powder cocaine (13%, n=46).  
Traditional drug use within the last month amongst NPS users is laid out in Figure 
3.1 overleaf. Over half had used cannabis (57%, n=143), two fifths had used 
benzodiazepines (41%, n=103) and almost a third (32%, n=82) had used heroin 
within the last month. 
                                         
43
 Participants for the survey were recruited primarily through services including homeless drop ins. To 
increase reach, participants were also recruited online. The majority of surveys were by clients of services, 
however a small proportion were completed online by individuals not necessarily in contact with services. 
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Figure 3.1. Last month traditional drug use among NPS users 
 
 
 
 
 
 
 
 
 
 
 
Base: 252 respondents who reported ever taking NPS 
3.1.2 Routes of Administration 
Preferred route of administration varied by substance (detailed in figure 3.2). For 
people who had used NPS in the last 6 months:  
 Of the 93 people who answered the question on routes of administration for 
synthetic cannabinoids, 91 respondents (98%) reported smoking. 
 Of the 87 people who answered the question on routes of administration for 
benzodiazepine-type NPS, 57 respondents (66%) reported taking it orally 
and 24 respondents (28%) reported taking it sublingually.44  
Both stimulant-type NPS and mephedrone were taken in more diverse ways: 
 Of the 49 people who answered the question on routes of administration for 
stimulant-type NPS, 25 respondents (51%) reported snorting and 16 
respondents (33%) reported injecting. Smaller numbers reported swallowing 
and smoking. 
 Of the 44 people who answered the question on routes of administration for 
mephedrone, 26 respondents (59%) reported snorting and 12 respondents 
(27%) reported injecting. Smaller numbers reporting swallowing and 
smoking. 
                                         
44
 Sublingual is under the tongue administration 
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Fig 3.2: Reported NPS use and preferred route of administration
45
 
  
 
 
 
 
 
 
 
 
 
 
 
Base46: (synthetic cannabinoid users n=93, benzodiazepine-type NPS n=87, stimulant-type 
NPS n=49, mephedrone n=44) 
3.2  People who inject drugs 
Based on the analysis of needle exchange data for NHS GGC and NHS Lothian, 
we estimate that there are 190 (confidence interval 114-265)47 injecting NPS users 
in NHS GGC and a further 673 (confidence interval 562-784)47 NPS injectors in 
the NHS Lothian area48.  
The NPS survey provides information on 141 people who inject drugs. The levels 
of NPS use recorded were high. 96% (n=136) of this group reported ever using 
NPS. The most frequently reported NPS used by this group in the last six months 
were: 
 Benzodiazepine-type NPS (58%, n=82), and 
 Synthetic cannabnoids (68%, n=48). 
                                         
45
 For benzodiazepine-type NPS, sublingual (under the tongue) was the most common „other‟ selection, 24 
out of 29 responses 
46
 Number of respondents varied by drug type question which is indicated by n= 
47
 A confidence interval gives an estimated range of values which is likely to include the true value 
48
 The method used to produce population estimates from a single data set is known as truncated Poisson. 
Details on this method can be found in the technical appendix to this report (Appendix A). 
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Amongst all PWID, 33% (n=47) reported injecting NPS in the last six months. This 
was almost exclusively stimulant-type NPS including mephedrone, ethylphenidate 
and cocaine-type NPS:  
 
 Of the 30 injecting NPS users who had used mephedrone in the last six 
months, half (n=15) had injected it 
 Of the 33 injecting NPS users who had used cocaine-type NPS in the last 
six months, nearly two thirds (n=20) had injected it 
 Of the 14 injecting NPS users who had used ethylphenidate in the last six 
months, 12 had injected it.  
 
Nine people reported currently injecting NPS.  For those that did, the average 
frequency for injecting was 5 times per day and people reported incidences of 
equipment sharing and poor injecting technique such as not filtering49,„missed 
hits‟50 or using citric acid51 which is not required for the majority of NPS. 
PWID were most likely to source NPS from: 
 Shops (48% n=67) 
 Dealer (47%, n=66) 
 Friends or family (34%, n=47) 
Small numbers of PWID sourced online (8% n=11) or selected „other‟ (5%, n=7). 
Some respondents sourced from multiple sources. 
3.3 Mental health service users 
The NPS survey gained information from 99 people currently in contact with 
mental health services.  It found that 95% (n=94) of respondents to the survey, 
who were currently in contact with mental health services, had ever used NPS. 
The most frequently reported NPS used by this group in the last six months were: 
 
 Synthetic cannabinoids (55%, n=52) 
 Benzodiazepine-type NPS (49%, n=46) 
 Stimulant-type NPS (not including ethylphenidate) (31%, n=29), and 
 Mephedrone (22%, n=21) 
                                         
49
 Substances prepared for injection should be filtered to remove impurities from the substance 
50
 Missed hits is a term used for missing the vein in an intravenous injecting episode and can be a factor in 
developing infections and swelling 
51
 Citric acid is one method for breaking down drugs such as heroin in to an injectable form. As stimulant-
type NPS are generally water soluble, they do not require use of an acid to prepare for injection.  Using 
citric acid when it is not required can contribute to irritation at the injecting site. 
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All respondents used NPS with other drugs.   
Mental health service users sourced NPS from: 
 Shops (47%, n=44) 
 Dealer (40%, n=38) 
 Friends or family (35%, n=33) 
Small numbers reported sourcing online (11%, n=10) or selected „other‟ (6%, n=6).  
Some respondents sourced from multiple sources. 
3.4  Vulnerable young people 
The NPS survey gained information from 69 vulnerable young people.  It found 
that 56% (n=39) of vulnerable young people who responded to the survey had 
ever used NPS. The most frequently reported NPS used by this group in the last 
six months were: 
 
 Synthetic cannabinoids (48%, n=19) 
 Benzodiazepine-type NPS (31%, n=12) 
 Mephedrone (23%, n=9), and 
 Stimulant-type NPS (not including ethylphenidate) (21%, n=8) 
One respondent reported using NPS only, with the rest combining NPS use with 
traditional drugs. 
 
Vulnerable young people sourced NPS from: 
 Shops (51%, n=20) 
 Friends or family (31%, n=12) 
 Dealer (26%, n=10) 
Small numbers reported sourcing online (15%, n=6) or selected „other‟ (5%, n=2).  
Some respondents sourced from multiple sources. 
3.5  Homeless people 
The NPS survey gained information from 92 people currently affected by 
homelessness, this included people in homelessness projects and rough sleepers.  
It found that 87% (n=76) had ever used NPS. The most frequently reported NPS 
used by this group in the last six months were: 
 
 Synthetic cannabinoids (63%, n=48) 
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 Benzodiazepine-type NPS (59%, n=45) 
 Stimulant-type NPS (not including ethylphenidate) (21%, n=16), and 
 Mephedrone (17%, n=13) 
All respondents used NPS with other drugs.   
People affected by homelessness sourced NPS from: 
 Dealer (54%, n=41) 
 Shops (49%, n=37) 
 Friends or family (35%, n=27) 
Small numbers reported sourcing online (7%, n=5) or selected „other‟ (4%, n=3).  
Some respondents sourced from multiple sources. 
3.6  Men that have sex with men (MSM)  
The NPS survey gained information from 70 men who identified as MSM.  It found 
that 54% (n=38) had ever used NPS. The most frequently reported NPS used by 
this group in the last six months were: 
 
 Mephedrone (37%, n=14), and 
 GHB/GBL (32%, n=12) 
There were small numbers using other types of NPS including benzodiaepine-type 
NPS (13%, n=5) and synthetic cannabinoids (10%, n=4).  All respondents used 
NPS with other drugs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
From the 30 MSM who answered where they sourced NPS from, respondents said 
they got NPS from: 
 Dealers (43%, n=13) 
 Shops (43%, n=13) 
 Friends or family (40%, n=12) 
Small numbers reported sourcing online  (7%, n=2) or selected „other‟ (7%, n=2). 
Some respondents sourced from multiple sources. 
3.7  Service Provider Survey Results 
The staff survey addressed staff perceptions of prevalence and trends in 
presentation. The majority of staff surveyed were from Tayside (21%, n=38), 
Lothian (20%, n=37) and Greater Glasgow & Clyde (GGC) (17%, n=32) NHS 
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regions.  The majority worked with people with mental health issues (84%, n=154), 
homeless people (74%, n=136) and PWID (72%, n=132). 70% (n=128) worked in 
drug and alcohol support services.  
3.7.1 Service Provider Perception of Client Drug Use  
In most services, staff perceived that the bulk of clients took only traditional drugs, 
with 65% (n=114)52 of staff perceiving that more than half of their clients only used 
traditional drugs. In comparison to this, 84% (n=101) of staff responding to this 
survey felt that less than a quarter of their clients only used NPS. 12%53 (n=19) of 
staff thought that more than half of their clients used both traditional drugs and 
NPS. Further detail is laid out in Figure 3.3. 
Fig. 3.3: Staff perception of client drug use by percentage of client group 
presenting for NPS, traditional drugs or both 
   
   
  
  
 
 
 
 
 
 
Base54 (respondents to question on only traditional drug use n=175, only NPS n=120, both 
traditional drugs & NPS n=158) 
3.7.2 Staff Perceptions of Client Presentation over Time 
When asked about how patterns of presentation in relation to NPS use and 
traditional drug use had changed over the previous six months, overall staff felt 
that things had remained largely the same. This is described in Fig. 3.4 overleaf.  
                                         
52
 Combining only traditional drug use figures from 51-75% and 76-100% as described in Fig.4.2 to total 
65%  
53
 Combining figures from only NPS use figures from 51-75% and 76-100% as described in Fig.4.2  to total 
12%  
54
 Numbers of respondents varied by question which is indicated by n=  
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 Fewer staff (18%, n=33) felt that they had seen a decrease in „NPS only‟ 
presentations since autumn 2015, compared to those that had seen an 
increase (25%, n=46) in NPS only presentations.  
 A lower proportion of staff (14%, n=26) felt that they had seen a decrease in 
combined NPS and traditional drug presentations since autumn 2015 than 
had seen an increase (26%, n=47).  
This suggests that trends are not consistent across all regions and all services, but 
that there has potentially been a slight upward trend in presentations related to 
NPS use to services since the autumn of 2015.  
Fig. 3.4: Staff Perception on Patterns of Presentation: Spring 2016 compared to Autumn 2015 
 
 
 
 
 
 
 
 
 
 
 
 
Base (n=183) 
Service providers were also asked which NPS were of particular concern. 57% of 
staff reported concern about benzodiazepine-type NPS, and 53% reported 
concern about mephedrone use. All NPS that cause staff concern are described in 
Table 3.2. 
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Table 3.2: NPS staff worry about 
Service Type N % 
Benzodiazepine-type NPS 105 57 
Mephedrone 97 53 
GHB/GBL 50 27 
Ethylphenidate 35 19 
Salvia 31 17 
None of the above 20 11 
 
 
3.8  Discussion 
The prevalence of NPS use among vulnerable populations in Scotland remains a 
challenge to measure.  The under reporting of NPS use by vulnerable populations 
to services highlighted in the survey combined with limited existing data within 
services and availability of national data sets meant that developing a complete 
estimate of prevalence was not possible.  
Nonetheless, this chapter has begun to develop our knowledge of patterns of NPS 
use amongst key vulnerable groups in Scotland. Of those completing the NPS 
survey, over half reported having ever used NPS, although the last six month use 
rate was lower. This could suggest a downward trend in NPS use, or a high rate of 
NPS experimentation compared to continued use. Staff perceptions of trends were 
of an overall slight upward trend in NPS-related presentation, although these 
varied geographically and by type of service.  
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4. Motives for NPS Use 
4.1 Introduction 
This chapter examines the motivations for initially trying NPS, stopping use after 
trying, and continuing to use. It also draws on staff explanations from the focus 
groups as to why some clients do not try NPS at all. This data is supplemented by 
quotes from the qualitative analysis of interviews with people who had used NPS 
and from focus groups with frontline staff. 
The analysis focuses primarily on the use of synthetic cannabinoids, 
benzodiazepine-type NPS, stimulant-type NPS, and mephedrone as these were 
the most popular NPS across all populations. The exception to this was amongst 
MSM who reported low rates of synthetic cannabinoid use and high rates of 
GHB/GBL use. Where relevant, the analysis is broken down by groups.  
The four most frequently reported reasons given for trying NPS were ease of 
access, curiosity, the socially embedded nature of substance use, and price. In 
addition, substitution for other drugs (both deliberate and accidental), improving 
sex, and health-related reasons were key motivations associated with specific 
substances.  
4.2 Trying NPS  
4.2.1 Ease of Access 
Of those who reported using a substance within the last 6 months, „It was easy to 
get‟ was given as one of the most common reasons for trying NPS. This was the 
case for: 
 38% (n=40) of the 104 people who reported synthetic cannabinoid use  
 43% (n=23) of the 53 people who reported stimulant-type NPS use, and  
 40% (n=41) of the 102 people who reported benzodiazepine-type NPS 
use. 
This also emerged in the interviews, with participants discussing ease of access: 
 online (“It was just easier to get them [NPS] online)”55 
 via shops (“I found out where to get it [synthetic cannabinoid] during the 
day)”56, and  
                                         
55
 Peter, Young Person, Homeless 
56
 Colin, Mental Health Service User 
28 
 
 from dealers: “It‟s easier to get a hold of than hash or grass and stuff.  
Everyone is buying from down the street [i.e. from a street dealer] because 
it‟s £6 bags” 57. 
4.2.2 Curiosity and Friendship 
Amongst those who reported using a substance within the last six months, the 
statement ‘Because I wanted to try it’ was given as another main reason for 
trying NPS. This was the case for: 
 44% (n=21) of the 48 people who reported mephedrone use  
 34% (n=18) of the 53 people who reported stimulant-type NPS use, and  
 17% (n=17) of the 102 people who reported benzodiazepine-type NPS 
use.  
This was supported by data from the staff survey, with 66% (n=122) of those 
working in services reporting that they believed their clients experimented with 
NPS because they had wanted to try it. 
The statement ‘My friend had it’ was another common reason for trying NPS 
amongst those who reported using NPS in the last six months. This was the case 
for: 
 42% (n=44) of the 104 people who reported synthetic cannabinoids use, 
and 
 42% (n=20) of the 48 people who reported mephedrone use. 
This was similarly supported by data from the staff survey, with 56% (n=103) of 
those working in services reporting that they believed their clients experimented 
with NPS because they were offered it by a friend.  
In the qualitative interviews, participants often linked curiosity and sociality.  When 
discussing trying mephedrone for the first time, various reasons were given.  The 
common themes were: 
 meeting new people (“It was a new crowd of people that I started going 
about with”)58 
 hearing friends enthuse about NPS (“Everybody was raving about it 
[mephedrone], so why not, eh?”)59, and 
 seeing a given substance’s effects on others: “My pal looked like she 
was having a ball and I thought I want to try this [Ching – a stimulant]” 60. 
                                         
57
 Nick, Homeless 
58
 Moira, PWID 
59
 Jessica, PWID and Mental Health Service User 
60
 Claire, PWID, homeless, and mental health service user 
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4.2.3 Price and Potency 
While price and potency was not the primary motive for the use of any specific 
substance, the statement ‘it was cheap’ was amongst common reasons given by 
those who had used NPS in the last 6 months. This was the case for: 
 28% (n=29) of the 102 people who reported benzodiazepine-type NPS  
 30% (n=31) of the 104 people who reported synthetic cannabinoids use, 
and 
 30% (n=16) of the 53 people who reported stimulant-type NPS use.  
This was supported by data from the staff survey, with 58% (n=106) of those 
working in services reporting that they believed their clients experimented with 
NPS because they were cheap. 
Price emerged as a common theme in the interviews and focus groups, although it 
was often linked to potency in discussion, as illustrated in the following quote: 
 
“I think that‟s why I liked it [synthetic cannabinoids] so much when I started 
smoking it because it was £10 for a gram. You would literally roll it, you would 
take one draw, and that was all my thoughts and fears blocked out and that was 
me wasted instantly.”61 
 
4.2.4 Substitution for other substances  
Almost a quarter of synthetic cannabinoid users (22%, n=23) reported first using 
synthetic cannabinoids thinking they were something else.  
As illustrated below, this was rarely welcomed by those who discussed such 
experiences in the interviews:  
 
“I didn‟t know what it was. I was just thinking that it was a normal joint, and 
then I had a weird taste in my mouth. Then, all the effects started 
happening…. I don‟t think I would have tried it [had I known what it was] 
because when I was in [prison] there was people dropping dead, obviously.62 
63 
                                         
61
 Luke, Vulnerable Young Person 
62
 Daniel, Vulnerable Young Person 
63
 Note on prison deaths: any death in prison custody may lead to a Fatal Accident Inquiry (FAI) under the 
Fatal Accidents and Sudden Deaths Inquiry (Scotland) Act 1976 however the decision to hold an FAI is a 
matter for the Lord Advocate/Procurator Fiscal.  No cause of death is recorded where a death has not yet 
been determined following FAI.  No determination has been made that has recorded NPS as having 
contributed to or been the cause of a death in a Scottish prison. 
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A slightly higher proportion of people who had used benzodiazepine-type NPS in 
the last 6 months (29%, n=30) reported they tried them because „I thought it was 
something else‟. However, not all substitution was accidental. 26 people reported 
that they did so for „other‟ reasons (including for example, that they „couldn’t get a 
Valium prescription‟). Over a quarter (28% of reported benzodiazepine use, 
n=29) did so for health-related reasons: 
 
“They [benzodiazepine-type NPS] were advertised as benzos and I knew – 
I‟d taken Valium, benzos – so I knew that they worked [for managing 
sickness]. So these legal highs were not only cheaper but I was getting a lot 
more for my money… I was able to keep it going, maintain it instead of 
buying street Valium where I wouldn‟t be able to maintain it. So it was only 
about the sickness.” 64 
 
Others specified the kinds of mental health problems they felt benzodiazepine-
type NPS could help with, captured in the statement below:  
 
“I was prescribed diazepam for anxiety and I no longer had any of that so it was 
to kind of go on with that.” 65 
 
These references to prior benzodiazepine-use (prescribed or otherwise) and the 
emphasis on managing health rather than curiosity or pleasure-driven motives 
suggests that substitution (either deliberate or accidental) may play a much 
greater part in motives for trying benzodiazepine-type NPS than other types of 
NPS. 
4.2.5 Improving Sex 
15% (n=7) of the 48 respondents who ticked the „other‟ box as a motivation for 
trying mephedrone stated they had used it to enhance sex. Six of these seven 
respondents were MSM.  Similarly, in interviews the use of mephedrone and other 
NPS to enhance sex was discussed primarily, but not exclusively, by MSM:  
  
[You] get a buzz from it [mephedrone] but it‟s also part of a sexual experience 
as well.... It just makes the contact with, and normally there‟s one or two others 
at the same time so it just makes it much more sort of, yes, I mean, it is a more 
enjoyable experience I think.” 66 
 
                                         
64
 Tiffany, mental health service user 
65
 Michael, mental health service user 
66
 Hugh, MSM 
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During the interviews, four participants who did not identify themselves as MSM 
also described the use of NPS to enhance sex: 
    
“It [„Burst‟ – ethylphenidate] makes you f***ing sex daft. Total sex daft. You 
think you‟re a porn star, it‟s f***ing mad.” 67 
 
Male service users who identified as homosexual or bisexual were invited to 
complete an additional section of the NPS survey on chemsex. This was 
completed by twenty-nine of the 38 (76%) MSM who completed the main survey. 
Fig.4.1 illustrates that just under half (n=10) of the 23 individuals who identified as 
engaging in chemsex reported that over half of their sexual encounters involved 
the use of chems. 
Figure 4.1: MSM reporting experiences of chemsex and slamming 
 
 
  
 
 
 
 
 
 
  
 
Base (respondents to question on chemsex n=23, slamming n=6) 
Twenty-six MSM responded to a question asking what led them to use chems 
during their last chemsex encounter, the main reasons given were to enhance 
sensation (n=13), followed by being drunk or high (n=9) and because their 
partner/s were doing it (n=868).  
                                         
67
 Kevin, PWID 
68
 As described in Chapter 3, the most extensively used substances during last chemsex encounter were 
reported as alcohol, followed by GHB/GBL, mephedrone, cannabis and cocaine at much lower rates. Two 
participants reporting using ecstasy-type NPS and two using ketamine-type NPS. 
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Enhanced sensation also emerged as a theme in the interviews and focus group 
discussions with staff, as illustrated below:  
“When they [MSM] inject mephedrone it really heightens the sensitivity of the 
whole body.” 69 
 
 
MSM also reported increased confidence (n=14) and increased sexual function 
e.g. maintaining an erection (n=13) whilst under the influence of NPS. 
 
4.2.6 ‘Legal’ Highs 
Survey and interview participants were also asked about the importance of legality 
for trying NPS.  However, this motive appeared to be less influential than those 
described earlier. 
„It was legal‟ was descibed as a reason for trying NPS by less than one in eight 
(11%, n=21) NPS survey respondents. This suggests that legality was not a strong 
motivator for choosing NPS over „traditional‟ drugs, although the fact that some 
NPS were legal at time of use may have increased the ease of access.  
Legality did feature more prominently in focus group discussions with staff in 
services, as illustrated:  
 
“For our young women it‟s the cost, it‟s about cost. And it being legal as far as 
they‟re concerned as well, they‟re not going to end up in court for it.” 70 
 
Legality was also discussed by staff in relation to avoiding detection in drug tests 
and not risking arrest for possession.  
Links between legality and perceived safety were explored in the survey.  Only a 
very small number of participants who had used NPS equivalents to „traditional‟ 
drugs in the last 6 months did so because they thought they would be safer. 
This was the case for:  
 4% (n=4) of the 104 people who reported synthetic cannabinoid use 
 3% (n=3) of the 102 people who reported benzodiazepine-type NPS use, 
and 
 6% (n=3) of the 53 people who reported stimulant-type NPS use.  
                                         
69
 Lothian Focus Group 
70
 GGC Focus Group 
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Nonetheless, the prospect that the description of substances as „legal‟ could lead 
people to the mistaken view that they were also safe was raised during the 
interviews:   
 
“Like the way like it's put out, like as in, they say legal highs, it makes you think 
it's safe because it's legal”. 71 
 
However, Samuel, went on to reflect that:  
 
“The first time folk take it, they take it because they think it's safer, cheaper 
and better. But, it isn‟t safer, it's cheaper and like the strength, the intention to 
it obviously gets stronger, but it doesn't mean it's better.” 71  
 
Interviews also revealed that while apparent legality was not a motivator, the 
language of legality did shape how NPS were talked about. The most commonly 
used terminology to describe NPS was „legal highs‟, or „legals‟. This extended to 
some participants describing being under the influence of particular NPS, 
particularly synthetic cannabinoids, as being „legalled‟ (for example, “I just wanted 
to be high and legalled the whole time”).72 
It was clear from the interviews that knowledge about the legal status of various 
substances was inconsistent and could be confused:  
 
“I mean, they‟re all legal as far as I understand it. To be honest I never have 
paid much attention, but when it‟s something like that, yes, it‟s [mephedrone] 
not illegal, definitely not.” 73 74 
 
 
For some participants the legal status of substances when trying them for the first 
time was irrelevant (“I did not know and I did not care”).75 
Although the language of legality pervaded the ways in which some people who 
had taken, or continued to take, NPS talked about these substances – as both a 
category of drugs („legals‟) and an effect („being legalled‟) – knowledge about legal 
status was limited and had minimal impact on informing decisions to try NPS. 
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4.3 Not Trying and Stopping Use 
While interviewees and participants who completed the NPS survey beyond the 
demographics section had all used NPS, focus group participants and people 
completing the staff survey worked in services which also support people who 
have not used NPS but who have used traditional drugs.  These participants were 
able to give an insight into some of the reasons for not experimenting with NPS. 
The primary motives given by staff focused on relationships, perceptions of effects 
and effects on health. These are further discussed below. 
4.3.1 Information and Effects on Others 
The key reason for not using NPS identified by staff in the survey was that their 
clients had seen the effects of NPS in others. This was stated by over half of 
participants (56%, n=103). In the focus groups it was suggested that this may 
have been influenced by both seeing others, and information gathered from other 
sources:  
  
“A couple of young men that I work with I think it‟s just about information, that 
they‟ve read about it or they‟ve heard about it and have all said, “No I‟m not 
going to touch that s**t, no way”.... They‟d rather do whatever else it is they‟re 
doing than take a legal high.” 76 
 
These reasons also featured in interviewee accounts of stopping: 
 
“[I stopped because of] all the different stuff that I‟ve seen with other people 
that took it, like obviously ma pal jumping into the [River] and stuff like that. 
I‟ve heard of other people who have just stopped breathing on them so aye 
never touched them again.” 77 
 
“I did see on the Internet and stuff like that, and I have heard that just, 
because obviously I researched it myself, you know, and I do look at the 
documentaries and they‟ve scared me a bit so then that was another reason 
to stop, you know?” 78 
 
Just as effects on others could operate as a positive inducement to 
experimentation, they could also act as a deterrent to initial experimentation and 
continued use. Similarly, while information was understood by many to be difficult 
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to access79, what information they did access could discourage some people from 
using or continuing to use NPS.  
 
4.3.2 ‘I didn’t like it’ 
When asked why they had stopped using NPS, the main reason offered by people 
who had tried NPS in the NPS survey was ‘I didn’t like it’. This was the primary 
reason given by:  
 76% (n=42) of the 55 people who reported stopping synthetic 
cannabinoid use in the last 6 months 
 63% (n=19) of the 30 people who reported stopping stimulant-type NPS 
use in the last 6 months, and 
 60% (n=18) of the 30 people who reported stopping mephedrone use in 
the last 6 months. 
This was supported by data from the staff survey, with 38% (n=73) of those 
working in services reporting that they thought their clients stopped using NPS 
because they did not like the effects. 
In contrast, „I didn’t like it‟ was a reason offered by less than a quarter of those 
who had stopped using benzodiazepine-type NPS. This was cited by five of the 
23 respondents who answered this question. Instead, these participants were 
more likely to cite reasons around damage to physical health (n=8 respondents) 
and mental health (n=7 respondents).  
Importantly, interview participants distinguished between disliking immediate, 
intoxication effects, (“I wouldn‟t even try it [synthetic cannabinoid] again.... That 
really, really scared me”)80 and longer-term effects: 
 
“It was just [ethylphenidate] before they sort of got banned… I was destroyed, 
I was a corpse… I was like having nervous breakdowns, like proper 
breakdowns.” 81  
 
The theme of disliking intoxication effects and quickly stopping use featured most 
prominently in relation to synthetic cannabinoids, which is reflected in the very 
high rates of trying and stopping due to dislike of effects in relation to this class of 
substance. 
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4.3.3 Damage to Mental Health, Physical Health, and Relationships 
Amongst those who had reported using NPS in the survey, the statement ‘It was 
damaging to my mental health’ was one of the main reasons given for stopping 
use. This was the case for: 
 44% (n=24) of the 55 people who reported stopping synthetic 
cannabinoid use in the last 6 months 
 43% (n=13) of the 30 people who reported stopping stimulant-type NPS 
use in the last 6 months 
 33% (n=10) of the 30 people who reported stopping mephedrone use in the 
last 6 months, and 
 30% (n=7) of the 23 people who reported stopping benzodiazepine-type 
NPS use in the last 6 months. 
This was supported by data from the staff survey, with 69% (n=127) of those 
working in services reporting that they felt damage to mental health was a reason 
for their clients stopping NPS use.  
This also featured in the interviews as illustrated in the following: 
 
Interviewer: Tell me what made you stop [using mephedrone]. 
 
“I think hearing the voices and ending up in [a secure mental health unit].” 82 
 
 
Another main reason for stopping using NPS reported in the NPS survey was that 
‘It was damaging to my physical heath’. This was the case for: 
 47% (n=14) of the 30 people who reported stopping stimulant-type NPS 
use in the last 6 months, and 
 35% (n=8) of the 23 people who reported stopping benzodiazepine-type 
NPS use in the last 6 months. 
This was supported by data from the staff survey, with 39% (n=72) of those 
working in services reporting that they thought their clients stopped using because 
it was damaging to their physical health.  
Physical health damage was seen to be less significant by some: 
 20% (n=11) of the 55 people who reported stopping synthetic cannabinoid 
use reported they stopped using because it was damaging to their physical 
health, and 
                                         
82
 Andrea, Mental Health Service User, PWID 
37 
 
 17% (n=5) of the 30 people who reported stopping mephedrone use 
reported doing so because it was damaging to their physical health 
Nonetheless, damage to physical health was discussed by interview participants: 
  
Interviewer: And the main reason you stopped [Ching – a stimulant]? 
 
“Was because I nearly lost my arm”.83 
 
 
Among survey respondents, damage to relationships was not a significant driver 
towards stopping. However in the interviews, participants reflected much more 
extensively on the damage their NPS use had done to their relationships, 
discussing this as a more important driver for stopping than damage to their 
physical and mental health84. This often related to damaged relations with family 
members: 
  
“And then the family found out about it [synthetic cannabinoid use] and 
obviously they know about what it does… So I eventually just opened my 
eyes and realised what I was doing and stopped it again”. 85 
 
 
Staff were asked to identify the key difficulties they saw clients experience 
when trying to stop use of NPS. Identified barriers included: 
 
 anxiety (58%, n=106) 
 sleeping difficulties (54%, n=100), and   
 irritability (50%, n=92).  
This highlights a particularly challenging context for recovery and barriers for 
service users engaging with services. 
4.4 Continuing to Use NPS  
Rates of current use varied by substance, as illustrated in Table 4.1 overleaf.  The 
table illustrates use in the last 6 months and current use (although due to a 
significant proportion of the sample being recruited through treatment services, it 
should be noted that active use could be under-reported by clients who may have 
been concerned about disclosure of current drug use). 
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Benzodiazepine-type NPS had the highest rates of current use reported with 67% 
(n=58) reporting they currently used them.  
Table 4.1: NPS Use: Reported six month and current use 
NPS type 
Taken in last 6 months Currently take 
N % N % 
Synthetic cannabinoids 104 41 33 36 
Benzodiazepine-type 102 41 58 67 
Stimulant-type 53 21 13 28 
Mephedrone 48 19 10 24  
 
Those who reported using NPS in the survey gave various reasons for continuing 
to use their chosen NPS. These overlapped substantially with their reasons for 
trying. Ease of access was a main reason for continuing to use synthetic 
cannabinoids, benzodiazepine-type NPS and stimulant-type NPS. This was 
supported by the staff survey, where ease of access was the primary reason cited 
(54%, n=100).  
Price was also reported as an important reason for continued synthetic 
cannabinoid and stimulant-type NPS use in the NPS survey.  This was further 
reflected in the staff survey, with over half of respondents citing this as a reason 
for continued use amongst clients (51%, n=93).  
Similarly consistent with reasons for trying, the two other main reasons for 
continuing to use given by users of benzodiazepine-type NPS were that they 
couldn‟t access Valium, and for „health reasons‟. One interviewee in the 
qualititative interviews described continued use of benzodiazpeine-type NPS 
connected to dependency issues and to managing mental health: 
 
“Etizolam is something that I would say was more…like you know the other 
substances I would use them and then I would put them down but Etizolam I 
couldn‟t put that down. You know I had to have that every day, maybe like 
two or three times a day….. it took the edge off, it took the edge off just 
existing at this point” 86 
 
Where reasons for continued use did differ from reasons for trying was in relation 
to pleasure and compulsion: 
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 Of the 10 people who reported continuting to use mephedrone, 5 
respondents (50%) reported continuing to use because they liked it, and 
 Of the 13 people who reported continuing to use stimulant-type NPS, 6 
respondents (46%) reported continuing to use because they liked it. 
This was also supported by findings from the staff survey, where 47% (n=86) of 
respondents cited this reason for continued NPS use among their client group.   
Reflecting on their continued use of mephedrone one interviewee in the 
qualititative interviews  captured this sense of pleasure when he explained: 
 
“It‟s [mephedrone] a pleasurable thing. I think that‟s why anybody does 
anything, whether it‟s drugs or alcohol or get high on gambling or whatever. 
It‟s a pleasurable thing. Like most things probably that are pleasurable it‟s a) 
either illegal or b) expensive or c) you can only do so much of it.” 87 
 
However, 41% (n=13) of people reporting continued synthetic cannabinoid use 
stated that they continued to use „Because I can’t stop‟, and this reason was also 
suggested by 39% (n=71) of staff. The interviews highlighted that some synthetic 
cannabinoids users found that while it was initially pleasurable, stopping proved to 
be difficult, and the withdrawal effects were challenging to manage. This could 
prompt continued use, as illustrated below: 
 
“Like some people do enjoy it [synthetic cannabinoids], but like when they're 
trying to get off it they realise completely that they are addicted and that's 
when the withdrawals start coming in, and most people can‟t handle the 
withdrawals because like you get sweats, cramps, sickness, headaches, 
migraines, fucking, just, oh it's bad like. It really is.” 88 
 
Overall the qualitative interview extracts suggested that pleasure and difficulty 
stopping were not necessarily straightforward to disentangle as motives.  
Of note is the low proportion of people who use benzodiazepine-type NPS who 
described their reasons for continued use in terms of difficulty stopping (19% of 
reported benzodiazepine-type use, n=11). 14 respondents stated that they used 
benzodiazepine-type NPS because they could not get Valium as a free-text „Other‟ 
response.   
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The difficulties reported in ensuring a continuous supply of benzodiazepines was 
illustrated in the qualitative interviews:  
 
“Actually I have bought pills out a shop. D something. Because I ran out of 
my pink pills, I ran out of them and that‟s the ones I bought from the shop. 
And it was going to take a couple of days, a day or two, for my pink pills to 
arrive. So I went into the shop and asked them, “I need to get something like 
vallies [Valium], benzos [benzodiazepines]”, and he said, “Try these”.” 89 
 
 
4.5 Discussion 
Motivations for trying, stopping and continuing NPS use varied. While the 
language used by interviewees to describe NPS emphasised legality (“legals”), 
few of the NPS survey participants or interviewees reported either trying or 
continuing use because they thought a given substance was legal. Similarly, 
safety did not emerge as a motivation for continued use.  The shift in perception 
between substances being „safer‟ because they were legal before trying, then 
going on to identify them as unsafe, after use, is mirrored in the work of Sheridan 
and Butler on BZP-party pills during the period in which they were legally available 
in New Zealand.90 
Instead, reasons for experimenting with and continuing to use focused for many 
on price and ease of access, as is noted noted by other research.91 In addition, 
curiosity, social relationships and pleasure were all important factors informing 
decisions to start, and stop use. Seeing effects in others could be an important 
draw to experimentation or an effective deterrent, highlighting the importance of 
social circles in normalising different types of drug use practices.92 
Participants reported increased pleasure, confidence and happiness as reasons 
for use of specific substances during chemsex. This is supported by existing 
qualitative research, which has identified better sex (in which pleasure is 
increased and inhibitions decreased) as a key motivation for engaging in 
chemsex.93 Enhanced sensation was also a key factor for those using NPS for 
chemsex. Research has identified sustained arousal, aided by the use of „chems‟, 
and heightened sensation as important motivators for use94. In addition, existing 
research has also identified that the use of chems can be used in response to 
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negative emotions such as low confidence or self-esteem, internalised 
homophobia and stigma around HIV status.  This suggests that „better sex‟ is 
complex to define, particularly in relation to MSM who engage in chemsex. Low 
rates of chem-free sex among MSM has been reported elsewhere95, highlighting 
the importance of use for sex among some MSM.  This suggests that chemsex is 
a potentially important public health issue, which will require responses that take 
account of the roles of pleasure and disinhibition, and chemsex social norms. 
The two main reasons for trying and continuing to use benzodiazepine-type NPS 
given by users were that they couldn‟t access Valium, and for „health reasons‟.   
This may simply reflect that dependency on these pharmaceuticals can be 
predicted after fairly short periods of regular use.96  Health reasons may include 
self-medication but may also be associated with managing unpleasant and 
potentially dangerous withdrawals as is reported in other literature.97  
Given that use of benzodiazepine-type NPS due to difficulty accessing diazepam 
was identified among the NPS survey respondents and taking account of the 
known issues of dependency and withdrawal with benzodiazepines98, this likely 
suggests this group did not report difficulties stopping because they were not 
seeking to stop their use. Rather, the difficulties people who took benzodiazepine-
type NPS reported were around ensuring a continuous supply. 
There is an extensive literature base which suggests that withdrawal from 
benzodiazepines involves potentially challenging symptoms. In some clients, 
withdrawal effects such as rebound anxiety and rebound insomnia, can have 
physical manifestations such as sweating and tremors99. Less well documented 
are the withdrawal effects of synthetic cannabinoid use, although respondents in 
the NPS survey identified similarly difficult withdrawal effects. Just as 
benzodiazepine withdrawal is ideally carefully clinically managed, clinical 
management may be beneficial to people who use synthetic cannabinoids and 
wish to reduce or cease their use. This is an area in need of further research with 
a view to the development of good practice guidelines.  
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5. Consequences of Use 
5.1 Introduction 
The consequences of NPS use were reported in the NPS survey and in interviews, 
as well as being described by staff through the staff survey and focus groups.  
5.2 Positive Effects 
Given that pleasure was reported as one of the motivators for use it is important to 
understand the positive effects of use as reported by NPS users. Positive effects 
were noted across all key NPS groups, although there were specific effects 
associated with different types of NPS.  
 
5.2.1 Stimulant-type NPS and mephedrone 
23 people reported on the health effects of stimulant-type NPS and mephedrone, 
which shared the same positive effects: 
 9 respondents reported that they made them more alert 
 8 respondents reported that they gave them more energy 
 6 respondents reported an improvement in mood 
Around half of people who have taken stimulant-type NPS or mephedrone (48%, 
n=11) stated that they continued to take these substances because they liked 
taking them, suggesting that the effects of alertness and energy were experienced 
as positive.  
 
5.2.2 Benzodiazepine-type NPS 
Fifty-eight respondents reported on the health effects of benzodiazepine-type 
NPS. Of these: 
 
 47 respondents (81%) felt their use reduced their anxiety 
 40 respondents (69%) felt that use made them more relaxed 
 22 respondents (38%) associated their use with improvements in mood 
This reflects the views reported in the previous chapter about health related 
motivations for starting and continuing benzodiazepine-type NPS.  
 
5.2.3 Synthetic cannabinoids 
31 respondents reported on the physical health effects of synthetic cannabinoid 
use. A key positive effect noted by one quarter (26%, n=8) of those who had taken 
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synthetic cannabinoids was sleep promotion. This was also described in the 
interviews:  
 
Interviewer: And what would you say you enjoyed about it the first time you 
used it [Bombay Blue – synthetic cannabinoid]? 
 
“The sleeping. I loved it.” 
 
Interviewer: And is sleeping difficult for you? 
 
“Yes. I don‟t sleep very good.” 100  
 
 
However, the sleep-promoting effects of synthetic cannabinoids were not always 
experienced as unequivocally positive. This is discussed in more detail in the 
section below. Around one fifth (21%, n=7) reported that use made them more 
relaxed.  
5.3 Negative Effects 
Negative effects were identified by interviewees in relation to intoxication and 
„comedowns‟ and by NPS and staff survey respondents in relation to mental 
health, physical health, social and relationship effects.  These are discussed 
below.  
 
Intoxication Effects and ‘Comedowns’ 
Interviewees in the qualitative interviews sometimes described positive intoxication 
effects of NPS use, however they were frequently understood to have negative 
effects subsequent to use. These two phases of intoxication – positive and then 
negative – were integrated experiences for some:  
 
 
“MCAT [mephedrone] – at the time I felt banging – the next day I felt like a 
total junkie. The come down off it was a fucking horrible, man – horrible. It 
was the worst comedown I've ever had in my life.... I felt so disgusting.” 101  
 
 
 
In addition, unwelcome intoxication effects were noted by interviewees, 
particularly, but not exclusively, in relation to synthetic cannabinoids. These 
included nausea (“I spewed everywhere [after taking a synthetic cannabinoid]”)102 
in one case loss of bladder control (“A pished myself [after taking „Burst‟ – 
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ethylphenidate]”)103 and general feelings of being unwell (“I actually thought I was 
going to die on that thing [Sensate – a synthetic cannabinoid]”)104.  
5.4 Mental Health Harms 
Staff and those who reported using NPS often differed in their views on the mental 
health effects of NPS in both the quantitative and qualitative elements of this 
study.   
 
When asked in the survey about the effects of taking NPS on their mental health, 
small numbers of respondents across all groups reported positive effects as a 
result of use, however larger numbers reported negative mental health effects, in 
particular anxiety and paranoia, mood swings, depression and psychosis.  
 
5.4.1 Anxiety and Paranoia 
Across current NPS users overall, 25% (n=47) described use as increasing 
anxiety and 12% (n=22) reported experiencing paranoia as a result of use.  
 
33 respondents who had used within the last 6 months provided information on 
mental health impacts of synthetic cannabinoids.  Increased anxiety was 
identified by: 
 
 Two in three (67%, n=22) people who had used synthetic cannabinoids 
within last 6 months 
 
 Increased anxiety was also identified by over half (54%, n=99) of staff 
working with synthetic cannabinoid users.  
 
23 respondents provided information on mental health impacts of stimulant-type 
NPS and mephedrone.  An increase in anxiety was identified by: 
 
 43% (n=10) of people who had used within the last 6 months 
 
 This was also the most frequently cited mental health effect noted by staff 
for mephedrone (34%, n=62) and stimulant-type NPS use (31%, n=57).  
 
There was therefore a strong correlation between the perception of staff and those 
who reported using NPS about the role of synthetic cannabinoids, stimulant-type 
NPS and mephedrone in increasing anxiety. However, there was a noticeable 
difference in perceptions of the anxiety-producing effects of benzodiazepine-type 
NPS between those who took them and staff.  
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 Four in five of benzodiazepine-type NPS users (81%, n=47) said that use 
reduced their anxiety. 
 
 42% (n=77) of staff felt that the use of benzodiazepine-type NPS increased 
anxiety in those who took it.  
 
Anxiety was also discussed by a number of interviewees in the qualitative 
interviews who reported use of these substances, particularly among those whose 
use was sustained. In particular, feelings of anxiety were often experientially 
bound up in feelings of paranoia, and to a lesser extent depression:   
 
 
“It can cause like quite a lot of anxiety obviously because if you're fearful of 
like whether you're going to die on it [synthetic cannabinoids] or not, but like 
depression can be quite a big one off it too. Paranoia, because you can think 
people are talking about you behind your back, stuff like that, folk are looking 
at you.” 105  
 
 
Overall, 17% (n=32) reported experiencing both anxiety and paranoia.  
 
This overlap between anxiety and paranoia came out particularly strongly in 
survey results with people who had taken synthetic cannabinoids: 
 
 almost as many synthetic cannabinoid users reported paranoia as a mental 
health effect (64%, n=21) as anxiety (67%, n=22), and 29% (n=10) reported 
both.  
 
Similarly, as many stimulant type NPS users cited paranoia as a mental health 
effect (38%, n=5) as anxiety (38%, n=5), and 23% (n=3) reported both.  
 
5.4.2 Mood Swings 
Across those who had used NPS in the last six months, 15% (n=28) described 
mood swings as an effect of use. Mood swings were a main effect of use reported 
by almost half of the 13 respondents who reported on health effects of taking 
stimulant-type NPS (46%, n=6). This finding was supported by results for the staff 
survey, where it was the primary mental health effect identified in relation to 
stimulant use, cited by 32% (n=58) of staff working with people who use stimulant-
type NPS.  
 
Although not a main effect reported by those who took benzodiazepine-type NPS 
or mephedrone, mood swings were nonetheless a main mental health effect noted 
by 36% (n=67) of staff in relation to the use of benzodiazepine-type NPS and 30% 
(n=55) of staff in relation to mephedrone use. 
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Mood swings were discussed infrequently in interviews, and tended to be in 
relation to withdrawal rather than being under the influence: 
 
 
 “Mood swings, you know, in a state of anxiety at times when I couldn‟t get 
any gear [mephedrone].” 106 
 
 
5.4.3 Depression  
Across those who had used NPS in last six months, 20% (n=38) described 
depression as an effect of use. Apart from mood swings, depression specifically 
was not reported as a main mental health effect in the NPS survey for any 
substance.  
 
However, depression was noted by 25% (n=45) of staff in relation to any NPS.  It 
was the second most common mental health effect of benzodiazepine-type NPS 
use, cited by 39% (n=71) of staff. It was also the third most commonly cited mental 
health effect of synthetic cannabinoids noted by staff (48%, n=88). GHB/GBL, 
which was taken almost exclusively by MSM, similarly produced concerns about 
depression among 16% (n=30) of staff working with people who used these 
substances. 
 
5.4.4 NPS and Underlying Mental Health Conditions 
37% (n=94) of those who reported NPS use in the NPS survey were or had 
previously been in contact with mental health services. 52% (n=96) of staff 
identified exacerbating underlying mental health conditions as an effect of NPS 
overall. Of the four key NPS, this was highest for synthetic cannabinoids, and 
lowest for mephedrone.  
 
Figure 5.1 gives an overview of staff perceptions on exacerbation of mental health 
by substance type. 
  
                                         
106
 Alexander, MSM 
47 
 
Fig. 5.1 Percentage of staff identifying exacerbation of underlying mental health conditions as an 
effect of NPS use by NPS- type.107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base (n=184) 
 
The interviews highlighted a range of different views, with some interviewees 
suggesting that their use of NPS had exacerbated their underlying mental health 
conditions: 
 
“Aye but I‟ve got the paranoia with the schizophrenia and that any way, so 
obviously that [ethylphenidate] made it worse.” 108 
 
 
 
Others, however, felt that their mental health conditions were due entirely to their 
NPS use:  
 
“My anxiety is bad, very bad and it‟s due to legal highs because I wasn‟t like 
that before I‟d taken legal highs.” 
 
Interviewer: Had you had any mental health problems before you used legal 
highs? 
 
“No.” 109 
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Others still, felt that their mental health conditions were entirely unrelated to their 
NPS use: 
 
 
“Although I do suffer from depression, I don‟t link that to legal highs.” 110  
 
 
This range of views was not consistent by either NPS of choice or type of mental 
health condition.  
 
In focus group discussions with staff, NPS was seen to exacerbate underlying 
mental health conditions. It is important to note that very few survey or interview 
participants had used NPS exclusively and had other risk factors which could 
contribute to mental health issues including homelessness, adverse childhood 
events and family health histories. Therefore, although some participants 
attributed their mental health problems to their NPS use, it is not possible from this 
data to determine causality.  
 
5.4.5 Psychosis 
Psychosis was not specifically asked about in the NPS survey apart from the 
chemsex section as it did not emerge as a key theme in the qualitative interviews 
outside of MSM interviews.  Very small numbers of MSM (n=3) reported psychosis 
as a mental health effect. It was not reported as a key mental health effect in the 
NPS survey for any substance. However, psychosis was the third most common 
mental health effect of stimulant-type NPS noted by staff, identified by 30% (n=55) 
of staff working with people who use stimulant-type NPS. Ethylphenidate, which 
was taken primarily by PWID, similarly produced concerns about psychosis among 
19% (n=34) of staff working with ethylphenidate users.  
 
Psychosis was discussed in focus groups, and one staff respondent felt that it was 
the move from heroin use to ethylphenidate use by their clients that had triggered 
an increase in psychosis across the population. 
 
 
“All our clients, previous heroin users, had mental health problems but no 
mental illness, you know, working for years with no mental illness and then 
they start taking these legal highs and then they were displaying symptoms of 
psychosis, and some who will never recover from it and will be on medication 
for the rest of their lives”. 111 
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Another staff respondent highlighted the role of additional factors in psychotic 
symptoms including other drug use and sleep deprivation. 
 
 
“It‟s difficult to sort of disentangle sometimes whether it‟s people stopping 
their heroin use as well, a lot of people sort of managing their behaviours with 
a lot of heroin and then when they stop using that and also not quite sure 
how much, we‟re attributing a lot to the drug, but just not sleeping for five 
days is very bad for you and I wonder, it would be interesting to sort of see 
how much of it is about sleep deprivation, the strain of psychosis that goes 
on. We‟re attributing a lot to this drug I think, but I don‟t know, but I do wonder 
how much, because people who drop their heroin use, sort of managing their 
behaviours sometimes.” 111 
 
5.5 Physical Health Harms 
There was more consensus in terms of staff and NPS users‟ perceptions of effects 
in relation to physical health than there was for mental health effects. When asked 
in the NPS survey about the effects of taking NPS on their physical health, across 
NPS users who had used in the last 6 months the main harms identified were 
problems with co-ordination (20%, n=38), difficulty sleeping (20%, n=37), and 
increased or decreased heart rate (14%, n=26).  
  
The main physical health effects reported by those who had taken synthetic 
cannabinoids were exclusively negative. The main physical health effects reported 
in relation to benzodiazepine-type NPS, stimulant-type NPS and mephedrone 
were more ambivalent, with respondents including improvements to physical 
health as well as harms among their main effects.  
 
5.5.1 Sleep Difficulties 
Amongst those who reported currently using NPS in the NPS survey, 20% (n=37) 
reported difficulties sleeping. This was given as one of the main physical health 
effects by people who had used synthetic cannabinoids, stimulant-type NPS or 
mephedrone in the last six months.   
 
 Of the 13 people who currently use stimulant-type NPS, 9 respondents 
(69%) reported that their use made sleeping more difficult for them. 
 
 Of the 10 people who currently use mephedrone, 6 respondents (60%) 
reported that their use made sleeping more difficult for them. 
 
This was supported by data from the staff survey. Staff identified sleeping 
difficulties amongst their clients in relation to stimulant-type NPS (36%, n=67) and 
mephedrone (30%, n=56).  
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In relation to benzodiazepine-type NPS, there were conflicting views amongst 
NPS users and staff: 
 
 91% (n=52) of benzodiazepine-type NPS users reported improved sleep  
 
 11% (n=6) of benzodiazepine-type NPS users reported sleeping difficulties, 
and  
 
 16% (n=30) of staff linked sleeping difficulties to benzodiazepine-type NPS 
use amongst their clients. 
 
Difficulty sleeping as a result of synthetic cannabinoid use was also reported by 
both NPS users and staff: 
 
 36% (n=11) of synthetic cannabinoid users who had used in the last six 
months reported difficulty sleeping in relation to synthetic cannabinoids 
 
 26% (n=8) reported improved sleep, and 
 
 29% (n=53) of staff linked synthetic cannabinoid to sleeping difficulties 
amongst their clients. 
 
Interview data revealed that taking synthetic cannabinoids often promoted sleep. 
Whereas this was viewed positively by some, such as Debbie (Section 5.2.3), 
others saw this sleep-promoting property as having a negative effect on their 
wellbeing (“I was constantly tired, I was never sitting up, I was always lying 
down”)112.  
 
It is important to note that NPS survey respondents did not describe what they 
regarded as a sleeping difficulty or improved sleep e.g. the quality of their sleep, 
duration, ease of getting to sleep or whether it was uninterrupted. 
 
5.5.2 Problems with Co-ordination 
Problems with co-ordination were reported by 20% (n=38) of the currently using 
NPS survey respondents. This was: 
 
 the primary physical health effect noted by people who have taken 
synthetic cannabinoids (42%, n=13)  
 
 the secondary physical health effect reported by people who have taken 
benzodiazepine-type NPS (46%, n=26) 
 
 not reported to be a health problem by any participants in relation to 
stimulant-type NPS or mephedrone use.  
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This is supported by findings from the staff survey.  Problems with co-ordination 
were seen as: 
 
 the main physical health consequence of benzodiazepine-type NPS use 
reported by 36% (n=66) of staff, and 
 
 a key consequence of synthetic cannabinoid use reported by 33% (n=60) 
of staff. 
 
By contrast, only 11% (n=20) of staff reported difficulties with co-ordination for 
either stimulant type NPS or mephedrone.  
 
5.5.3 Seizures 
Seizures were reported by 10% (n=18) of the currently using NPS survey 
respondents. Seizures were reported particularly by people who had used 
synthetic cannabinoids (39%, n=12). Seizures were not identified in the NPS 
survey as a main physical health effect of benzodiazepine-type NPS or stimulant-
type NPS and none of the 10 current mephedrone users who responded to the 
questions on the physical health effects of mephedrone identified seizures as 
being associated with its use. 
 
In contrast to this, only three staff respondents associated seizures with synthetic 
cannabinoid use. However, five staff did identify seizures as a main physical 
health effect of taking mephedrone.  
 
Seizures (commonly called „fits‟ or „fitting‟) were a fairly commonly physical health 
effect noted during the qualitative interviews, impacting on those who have taken 
synthetic cannabinoids, mephedrone, and ethylphenidate. However, interviews 
revealed an ambivalence among some towards the perceived risks of „fitting‟. Most 
who discussed seizures during interviews looked upon this as a negative 
consequence:  
 
 
“We had a joint out of it [Exodus – a synthetic cannabinoid], then I went all 
funny and all that on it and then I took a fit.... My sister saved my life from it, 
she found me after I‟d had that Exodus in a joint.” 113  
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However the experiences of fitting did not always act as a deterrent to continued 
use: 
 
 
“I remember of fitting, I remember of taking it [mephedrone] and then being in 
my bedroom and seeing my daughter, actually fitting, and seeing my 
daughter in her wedding dress. And I would see Jane, my mother-in-law, and 
then I would open my eyes to see an ambulance being there, eh. And I got 
took into the hospital, and then I'd come back out, and I'd still have four or 
five grams in my bra, and then I would do it again, eh. It was bad”. 114 
 
 
One respondent saw fitting as a positive marker of efficacy:  
 
 
“Most of the time [combining mephedrone with MDMA] was alright, but you 
would get the one person that would, or most of the time somebody was 
fitting or, most of the time me. If I didn‟t get a fit, I didn‟t think it was a good 
bit” 115 
 
 
While seizures were reported as a physical health effect by people who had used 
synthetic cannabinoids, and staff working with people who have used 
mephedrone, this does not necessarily mean that they were regarded as an 
unequivocally negative health experience, or a deterrent to future use.  
 
5.5.4 Hunger and Weight Change 
Decreased hunger was not a main physical health effect for people taking any of 
the four key NPS, and was reported by only 7% (n=14) of NPS survey 
respondents currently using NPS. Due to restrictions on the survey software, we 
were unable to give weight-loss as an option, so were required to phrase as 
decreased hunger. 
 
However, unplanned weight loss emerged as a key theme in interviews. 
Realisation of unplanned weight change was often presented in the context of 
relationships with others. Nick described how it was only after seeing his mother 
after a six-month gap that he realised the severity of his weight loss: 
 
“I didn‟t notice it was as bad as that at that point, but then it deteriorated until 
my mum came up, she hadn‟t seen me for six months, she said I looked like 
a junkie seeing how much weight I‟d lost. That‟s when I decided to wean 
myself off it [Exodus – synthetic cannabinoid].” 116 
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5.6 Social Effects 
174 NPS survey respondents reported on social harms of NPS use. The main 
social effects reported by NPS survey participants across all groups and all key 
NPS types were spending more money than planned or selling something to pay 
for NPS, and missed appointments. Staff survey respondents identified debt, loss 
of employment and education, loss of tenancy and anti-social behavior as the 
main social effects of NPS use, common across all key NPS types.  
 
5.6.1 Money and Debt 
Of the 174 NPS survey respondents who reported on social harms, 60% (n=105) 
reported spending more money than planned or selling something to pay for NPS. 
This was highest among people in contact with mental health services (67%, 
n=49).117 
 
Table 5.1 illustrates the borrowing and repaying data from NPS survey participants 
by risk group. 
 
Table 5.1: Borrowing & repaying debt 
 
 Total  
respondents  
Have ever 
borrowed 
money to pay 
for NPS 
Always been 
able to repay 
Never been 
able to repay 
N N % N % N % 
Homeless 75 44 58 22 49 3 7 
PWID 131 69 53 37 58 7 11 
Mental Health 
Service Users 
92 43 46 29 64 1 2 
Young People 35 15 43 8 56 2 13 
MSM 33 6 18 5 16 1 3 
Overall
118
  89 39 51 50 9 9 
 
In interviews, participants discussed borrowing (and stealing) from friends and 
family members, often resulting in damage to those relationships, selling 
possessions and pawning items to pay for NPS: 
  
                                         
117
 p<0.05 
118
 Overall figure from whole sample taking account of the cross over between different risk groups 
54 
 
 
 “Just borrowing off my dad, selling my hoose, selling my whole hoose. All 
I‟ve got left is my washing machine and my couch”. 119  
 
 
5.6.2 Missed appointments 
Use of NPS also correlated strongly with missed appointments. Of the 174 NPS 
NPS survey respondents who reported on social harms, 60% (n=104) reported 
missing appointments such as with the Job Centre, GP or treatment as a result of 
their NPS use. 
 
This was lowest among MSM (44%, n=10) and vulnerable young people (54%, 
n=14) and highest among homeless people (72%, n=41), people with in contact 
with mental health services (71%, n=52) and people who inject drugs (66%, 
n=67).120 Even among the groups with lower rates of missed appointments, almost 
half of these groups had missed an appointment due to NPS use.  
     
5.6.3 Education and Employment 
Loss of education and employment was the second most frequently identified 
social harm associated with NPS use in the staff survey after debt. Overall, it was 
identified by 49% (n=91) of staff, and specifically as: 
 
 the primary social harm associated with mephedrone use, identified by 
23% (n=43) of staff 
 
 a main social harm identified in relation to synthetic cannabinoids, 
identified by 32% (n=58) of staff, and 
 
 a main social harm identified in relation to benzodiazepine-type NPS, 
identified by 25% (n=46) of staff.  
 
Problems with work or employment did not appear as one of the three main harms 
identified by any group within the NPS survey except MSM, just over half of whom 
(52%, n=12) identified it as consequence of NPS use. 46% (n=12) of vulnerable 
young people and 32% (n=23) of people in contact with mental health services 
who answered the question on social effects of NPS use cited problems with work 
or employment as a consequence of NPS use. This suggests that while not 
among the most important effects identified by NPS survey respondents outside 
the MSM group, problems with work or employment nonetheless affected a 
notable minority of NPS survey respondents.  
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5.6.4 Loss of Tenancy 
Loss of tenancy was also frequently identified as a social harm associated with 
NPS use in the staff survey.  It was identified by 49% (n=90) of staff overall, and 
specifically by: 
 
 29% (n=54) of staff in relation to the use of synthetic cannabinoids  
 
 23% (n=43) of staff in relation to benzodiazepine-type NPS, and  
 
 21% (n=39) of staff in relation to stimulant-type NPS.   
 
Loss of home or tenancy did not appear as one of the top three main harms 
amongst any group in the NPS survey, being reported by 20% (n=35) of 
respondents who answered  a question on problems caused by NPS overall.  
 
Other social harms mentioned by front line workers in the staff survey were anti-
social behavior (particularly in relation to the use of benzodiazepine-type NPS and 
stimulant-type NPS), for which it was identified as a main harm.  In addition, 
increased aggression, involvement in sex work, the carrying of knives and other 
weapons due to paranoia and increased involvement in crimes such as shoplifting 
to fund NPS use were also other reported social harms by respondents to the staff 
survey. 
5.7 NPS Use and Relationships 
Taking NPS was seen by both NPS survey and staff survey respondents to affect 
relationships, particularly damaging relations with family and impacting on ability to 
fulfill caring commitments. Gender-based and intimate partner harms also 
emerged as a theme in qualitative data collection. 
 
5.7.1 Relations with Family, Partners and Friends 
Respondents to the NPS survey were asked to identify whether they thought the 
effect of their NPS use had a positive, no effect or a negative effect on key 
relationships. Across all groups the majority of respondents (47%, n=117) felt that 
taking NPS had had an overall negative effect on family relationships. Considering 
responses from each of the five population groups, MSM were the only group 
where this was not the top negative relationship impact. Qualitative data illustrates 
that this damage to relationships could extend from minor conflict to being 
disowned by family: 
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 “My full family disowned me a couple of weeks ago due to legal highs 
[synthetic cannabinoids], going to prison because I‟m stealing things, like 
stealing £6 out her [mum‟s] purse, tenners and that – wasn‟t thinking about 
that at the time, was just like that‟s another £6 man and that was a gram.... 
They‟ve just all disowned me.” 121 
 
 
Over a third of all respondents to the NPS survey reported experiencing a 
negative impact on their relationships with partners (37%, n=93). Interviews 
revealed that damage to relationships with partners often resulted in relationships 
ending, as John, quoted above, goes on to say: 
 
 
“My missus is trying to break it up, know what I mean. We did split up there 
for a while because obviously of legal highs and I almost lost my girlfriend 
through legal highs.” 121 
 
 
Across all groups, the third most impacted relationship was friendship, although 
63% (n=159) of respondents to the NPS survey reported that taking NPS had had 
no effect on friendship. Again, the interviews provided an insight into the nature of 
this type of harm, by highlighting damage to friendships due to either losing 
interest in friendship: 
 
“You basically just seclude yourself when you‟ve got these [synthetic 
cannabinoids]. I mean friends and family that I‟ve known for 20 years, I 
disowned them.” 122  
 
 
Or becoming isolated from non-NPS taking friends: 
 
“When I started smoking legal highs [synthetic cannabinoids], none of my 
friends wanted to be with me because I would be at a party and they would all 
be drunk and I would be sitting there rolling a legal joint and just sparking it up. 
Everybody would be like, “What's that smell? Is somebody smoking legals in 
this house?” I'd be like, “Yeah, it's me, what the fuck‟s your problem?” 123 
 
 
5.7.2 Fulfilling Caring Commitments 
Struggling to fulfill caring commitments was reported by 26% (n=45) of NPS users 
who answered the question on social harms of NPS. 
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 Of the 73 people in contact with mental health services who provided 
information on social harms, (33%, n=24) reported struggling to fulfill caring 
responsibilities 
 Of the 102 PWID who provided information on social harms, (26%, n=27) 
reported struggling to fulfill caring responsibilities 
 Of the 57 homeless people who provided information on social harms, 
(21%, n=12) reported struggling to fulfill caring responsibilities 
 Of the 26 vulnerable young people who provided information on social 
harms, (19%, n=5) reported struggling to fulfill caring responsibilities, and 
 Of the 23 MSM who provided information on social harms, (17%, n=4) 
reported struggling to fulfill caring responsibilities. 
Staff working with these populations also reported on whether they thought NPS 
had an impact on their clients‟ caring commitments. Over half of staff that worked 
with any group thought that NPS had an impact on fulfilling caring responsibilities 
(57%, n=105).  This ranged from 63% (n=83) of staff working with PWID to 55% 
(n=45) of staff working with vulnerable young people.  
 
Broken down by substance, difficulties with their clients managing caring 
responsibilities were reported by: 
 
 37% (n=68) of staff working with benzodiazepine-type NPS users 
 34% (n=63) of staff working with synthetic cannabinoid users 
 26% (n=47) of staff working with mephedrone users, and  
 23% (n=42) of staff working with stimulant-type NPS users. 
Where participants discussed children in interviews, they did not talk about 
difficulties they had managing childcare, but rather the role that parenthood played 
in decisions to reduce or stop their NPS use: 
 
Interviewer: What do you think the main things were that got you to stop 
[using mephedrone]? 
 
“Losing my son. They were gonna take him off me. And I just couldn't, I 
wouldn't have been able to live with myself.” 124  
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5.7.3 Gender-Based and Intimate Partner Harms 
For ethical reasons, gender-based and intimate partner harms were not asked 
about in the NPS survey, however they did emerge as a relationship theme in 
focus group discussion with front line workers. Concerns raised by staff focused 
primarily on concerns about consent in the context of chemsex (both among MSM 
and heterosexual couples), and concerns about the vulnerability of young women 
in public places due to intoxication, and sex-for-drugs relationships with vendors, 
particularly in shops were also highlighted.   
 
In addition to these harms which cut across all populations, a number of 
population-specific harms emerged.  
5.8 Population-Specific Harms 
Population-specific harms were identified in relation to chemsex among MSM, 
injecting NPS among PWID and unsupervised opiate detoxification among opiate 
users. These groups represent small sub-groups of total NPS survey respondents. 
However, considering them separately provides an opportunity to explore reported 
consequences of NPS use in more depth.  
 
5.8.1 Chemsex 
All MSM who had ever used NPS (n=38) were invited to complete an additional 
survey section on chemsex. This section of the report focuses on the 29 
respondents who completed this part of the survey, which addressed the physical 
and mental health effects of NPS use during their last chemsex experience. 
  
Of the 29 MSM who answered survey questions on chemsex, 15 reported no 
change to their mental health either during or after their last chemsex experience: 
 
 Just over half (n=15) reported feeling happier  
 
 Just under half (n=14) reported feeling more confident during their last 
chemsex experience, and  
 
 Just under one third reported feeling regret (n=9) and shame (n=8) after 
their last chemsex experience.   
 
Physical effects reported were increased sexual function during (n=13) and after 
(n=1) their last chemsex experience.   Under one quarter reported decreased 
sexual function during (n=7) and after (n=1) their last chemsex experience. Just 
under half (n=14) reported disturbed sleep after their last chemsex experience. 
Five reported blackouts during their last chemsex experience, one afterwards, and 
two both during and after their last chemsex experience.  
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Disinhibition following NPS use during sex emerged as a theme in interviews with 
MSM and some heterosexual participants.125 Interviewees discussed disinhibition 
leading to unsafe sexual practices. Disinhibition was also described as having an 
effect on drug choices, and routes of administration, including being injected by 
others. 
 
 
“At the end when I‟m trying to inject myself, so I‟m saying „Can you inject me 
now?‟”. 126 
 
 
The feelings of shame and regret noted above were also linked to disinhibition. 
 
 
“I even found myself doing things like, sexually, that I would just not entertain 
either, you know. Just 'cause I was like, away with it on this drug 
[mephedrone], you know.... Your inhibitions are just totally gone, and so I did, 
I found myself in situations that, you know, when I think back, like it does, it 
makes me cringe.” 127  
 
 
Twenty-four MSM answered questions about the social consequences of their last 
chemsex experience. Over half (n=15) reported no social consequences to their 
most recent chemsex experience. Slightly under one third (n=7) did identify having 
spent more money than they intended to. Three participants said that their last 
chemsex experience had resulted in damage to their relationship with their 
partner, and one said it had improved it. Two participants stated that they lost 
friends as a result of their last chemsex experience, in contrast to one participant 
who made new friends.  
 
5.8.2 Injecting NPS 
All PWID who completed the survey (n=141) reported taking traditional drugs, and 
of these, 97% also used NPS. Of those who used both traditional drugs and NPS, 
only 35% injected NPS (the remainder used other routes of administration). This 
section focuses on the 47 respondents who had ever injected NPS and the nine 
respondents who reported current injecting of NPS at the time of the survey.  
 
Among the nine current injectors, the majority (n=6) did so on a daily basis, an 
average of five times a day. Arms were the most popular injection site (n=8), but 
five reported they used multiple sites. All nine current injectors did so 
intravenously. Two always and four occasionally used vitamin C or citric acid to 
prepare their NPS.  
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Five out of nine reported sharing their needles and seven reported sharing 
injecting equipment. Six reported occasionally using without a filter and therefore 
not removing the impurities from the substance, increasing the risk of injecting 
related complications. 
 
When asked about their injecting experience, five said they often felt a burning 
sensation while injecting, and seven reported occasionally having irritation at the 
injecting site. Six occasionally experienced redness at the injecting site. Seven 
occasionally missed hits, four occasionally got infections. Seven of the nine never 
got abscesses and none reported collapsed veins. One of the nine had been 
hospitalised for their wounds.  
  
5.8.3 Unsupervised Opiate Detoxification 
Finally, a theme which emerged in the qualitative data was in connection to 
unsupervised opiate detoxification. This was most commonly associated with use 
of ethylphenidate and mephedrone.  
 
Some opiate users described the role of mephedrone or ethylphenidate in their 
reduced opiate consumption in positive terms, as illustrated below:  
 
 
 “Psychologically, you‟d forget to take your script and the next minute we 
were all clean.” 128  
 
 
However, staff working with these populations expressed concerns about 
medically unsupervised withdrawal from opiates and opiate replacement treatment 
(ORT) with NPS, with one noting a reverse trend back towards opiate use:  
 
 
“Yes a few of our guys after the ethylphenidate ban started using 
mephedrone and.... it was more expensive and they were also finding it 
heavy on their chest I think as well. I had reports of them feeling like they 
were going to have heart attacks and stuff with the mephedrone. So it‟s kind 
of gone back to heroin.” 129 
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5.9 Discussion 
There are a wide range of harms that span the use of different NPS.  It is difficult 
to attribute specific harms to specific substances definitively as harms experienced 
may be in part due to factors such as poly-use or pre-existing health issues. 
Harms are also interpreted differently (some „harms‟ aren‟t seen as such by some 
users).   
 
The NPS and staff surveys reveal important differences in perception of the 
mental health effects of NPS between those who have taken NPS and staff in 
services. Benzodiazepine-type NPS users identified use with reduced anxiety and 
increased relaxation.  In contrast, staff identified use of benzodiazepine-type NPS 
with increased anxiety. In line with discussion on motives for use, this can most 
likely be explained in terms of a concern of experiencing rebound anxiety130 and 
other withdrawal effects.131 This suggests a need to continue developing our 
knowledge of the consequences of NPS use and the impact of NPS on mental 
health and wellbeing in order to develop effective treatment responses.   
 
The vast majority of people who have taken benzodiazepine-type NPS and a 
minority of people who have taken synthetic cannabinoids reported improved 
sleep.  In contrast, improvements in sleep were not recognised as a physical 
health effect for either substance by staff. In addition, a number of respondents 
reported that synthetic cannabinoid use led to sleeping difficulties. Qualitative data 
suggest that these difficulties included both excessive sleep and being unable to 
sleep. Current research on cannabis use shows that withdrawal from sustained 
cannabis use can lead to sleeping difficulties132, suggesting a possible parallel 
with effects of synthetic cannabinoid withdrawal on sleep.  
 
The risk of overdose with benzodiazepine-type NPS is high, especially when used 
in conjunction with other substances.  This is evidenced by the role of 
benzodiazepine-type NPS in drug related deaths in Scotland.133 There are also 
clear risks in relation to potential patterns for overdose when someone returns to 
opiate use with a reduced tolerance. These risks are clearly documented with 
increased rates of overdose following liberation from prison.134 Both these issues 
highlight the need for improved information and treatment responses. 
 
There are also specific harms associated with patterns of use and route of 
administration. This highlights an information need for both NPS users and staff 
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who support them.  Patterns of behaviours such as frequent injecting or equipment 
sharing can lead to injecting related injuries including abbesses135 or risk of 
contracting blood borne viruses such as HIV and Hepatitis C.136  
 
Finally, this chapter has also shown that there are specific harms associated with 
population-specific groups such as chemsex amongst MSM, which impact on 
people who use NPS.  This poses a challenge for services to engage with 
populations not in treatment but whose NPS use and associated behaviours are 
likely to result in significant risks to those who use NPS and wider public health. 
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6. Treatment and Legislative Responses 
 
6.1 Introduction 
This final findings chapter addresses the views of people who have used NPS and 
staff who support NPS users in treatment. It explores how people who have taken 
NPS utilise available treatment services, where they currently get information on 
NPS and what changes they would like to see in available treatment. It finishes 
with a brief discussion of views on the Psychoactive Substances Act 2016. 
6.2 Contact with Services  
Reflecting the fact that over half of the data collection was carried out through 
services (59%, n=251) current contact with services was high across all groups. 
However, contact specifically related to NPS use was low.  Only 11% (n=26) of 
participants were in contact with one or more services relating to their NPS use.  
 
6.2.1 Contact with services: service type 
Fig. 6.1 displays the services that people who had used NPS were most in contact 
with.  The most commonly accessed were: drug services (58%, n=113), mental 
health services (43%, n=85) and homelessness services (39%, n=74).  The least 
utilised services were sexual health services (8%, n=15), mutual aid (22%, n=44), 
needle exchange (26%, n=47) and social work (28%, n=54). 
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Fig. 6.1: Service use by people who have taken NPS by service type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base (respondents who reported NPS use: sexual health n=180, mutual aid n=198, needle 
exchange n=179, social work n=195, homelessness n=192, mental health n=196, drug n=194)137 
 
6.2.2 Contact with Services: by group 
Rates of service use also varied by group. This section outlines service use in 
relation to each of the key groups who participated in the NPS survey.138 Table 6.1 
displays service contact data by group. 
 
                                         
137
 Number of respondents varied per question which is indicated as n= 
138
 Some of the target groups have cross over with other groups e.g. homeless and in contact 
with mental health services and so are therefore reported under both groups 
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Table. 6.1: Service use by people who have taken NPS by service type 
Group  NPS related 
service 
contact 
Type of service 
accessed for NPS 
Not in contact with 
service regarding 
NPS use 
Type of  services 
accessed (not NPS 
related) 
p-value 
MSM 
(n=32) 
6% (n=2) Mutual Aid (6%, n=2) 
Drug Services (4%, n=1) 
Sexual Health (4%, n=1) 
94% (n=30) Mutual Aid (10%, n=3) 
Drug Services (25%, n=7) 
Sexual Health (30%, n=8) 
 
(p<0.05) 
(p<0.001) 
(p<0.001) 
Homeless 
(n=74) 
11% (n=8) Drug Services (11%, n=8) 
Homelessness (3%, n=2) 
 
89% (n=66) Drug Services (69%, n=50) 
Homelessness (68%, n=49) 
 
(p<0.001) 
(p<0.001) 
PWID 
(n=127) 
13% (n=16) Drug Services (7%, n=8) 
IEP (3%, n=4) 
Homelessness (1%, n=1) 
Social Work (0%, n=0) 
 
87% (n=111) Drug Services (82%, n=98) 
IEP (42%, n=47) 
Homelessness (50%, n= 58) 
Social Work (34%, n=40) 
(p<0.001) 
(p<0.001) 
(p<0.005) 
(p<0.05) 
 
PWID (NPS-
injectors) 
(n=42) 
19% (n=8) IEP (11%, n=4) 
Drug Service (5%, n=2) 
Homelessness (0%, n=0) 
 
 
81% (n=34) IEP (51%, n=19) 
Drug Services (79%, n=30) 
Homelessness (67%, n=24) 
 
(p<0.001) 
(p<0.05) 
(p<0.01) 
 
Vulnerable 
Young People 
(n=35) 
 
14% (n=5) Drug Services (7%, n=2) 
Other (10%, n=1) 
 
86% (n=30) Drug Services (30%, n=8) 
Other (30%, n=3) 
(p<0.01) 
(p<0.05) 
 
Mental Health 
Service Users 
(n=90) 
20% (n=18) Mental Health (10%, n=9) 
Social Work (6%, n=5) 
Drug Services (6%, n=5) 
 
80% (n=72) Mental Health (90%, n=85) 
Social Work (41%, n=36) 
Drug Services (74%, n=67) 
 
(p<0.001) 
(p<0.001) 
(p<0.001) 
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6.2.3 Contact with Services: Reasons for not accessing support 
Of the 204 NPS survey respondents who reported that they were not currently in 
touch with services about their NPS use, 34 provided further information on their 
reasons for not accessing support.  
 
The most common reasons, which were consistent across all groups, were: 
 I don't have a problem (n=18) 
 I don't need help (n=9) 
 I am in recovery (n=9) 
 I don't know where to go for support (n=3) 
 There is nothing available for people who use legal highs (n=3) 
 I don't want to be seen there (n=3) 
 
6.2.4 Use of emergency services 
The survey data suggest that in the main, people who have taken NPS did not 
consider their NPS use as a reason to contact services. However, considerable 
numbers across all groups did rely on emergency services such as Accident & 
Emergency (A&E) and ambulances as a result of their use as described below in 
Table 6.2. Across all respondents: 
 
 32% (n=77) had called an ambulance for another person who had taken 
NPS, and  
 
 23% (n=55) had had an ambulance called for themselves.  
 
Table 6.2: use of emergency services in relation to NPS use 
 
 Total YP MH Homeless PWID MSM 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Had an ambulance 
called  for themselves 
as a result of NPS use 
55 
(23%) 
12 
(35%) 
28 
(30%) 
23  
(31%) 
34 
(25%) 
6 
(19%) 
Called an ambulance 
for another person 
affected by NPS use 
77 
(32%) 
12 
(35%) 
40 
(45%) 
29  
(39%) 
51 
(38%) 
6 
(19%) 
Attended A&E as a 
result of NPS use 
63 
(26%) 
14 
(41%) 
34 
(38%) 
23  
(31%) 
38 
(30%) 
8 
(26%) 
Been admitted to 
hospital for more than 
one night as a result of 
NPS use 
44 
(18%) 
5  
(15%) 
21 
(23%) 
14  
(19%) 
29 
(22%) 
7 
(22%) 
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Considering emergency service use by group (also shown in Table 6.2), mental 
health service users139 were most likely to call an ambulance for someone else 
(45% vs., group average of 32%), and MSM the least likely (19%).140 
 
Looking specifically at PWID, and comparing those who inject NPS and PWID as 
a group more widely, some differences emerged. Table 6.3 highlights that NPS 
injectors were more likely than the wider PWID group to have had an ambulance 
called for themselves (40% vs. 25%)139 and for another person (48% vs. 38%).140 
 
Table 6.3: comparison of PWID respondents‟ use of emergency services for NPS use 
 
 PWID – NPS 
injectors  
PWID – all 
injectors 
 N % N % 
Had an ambulance called for 
themselves as a result of NPS 
use 
18 40 34 25 
Called an ambulance for another 
person affected by NPS use 
21 48 51 38 
Attended A&E as a result of NPS 
use 
20 48 38 30 
Been admitted to hospital for 
more than one night as a result of 
NPS use 
15 35 29 22 
 
Looking at figures from both tables here, overall, rates for visiting A&E in relation 
to NPS use were high amongst respondents considered as vulnerable young 
people (41% vs. wider rate of 26%)140 and respondents who utilise mental health 
services (38%)140. A&E attendance was also higher for NPS injectors (48%)139 
than injectors more generally (30%), as was hospital admission for more than one 
night (35% of NPS injectors vs. 22% of general injectors, and a wider rate of 
18%)140. 
6.3 Providing Information and Support 
6.3.1 Sources of information used by people who use NPS 
216 NPS survey respondents answered a question on their sources of information 
about NPS. 
 31% (n=67) had not tried to find out about NPS at all 
 32% (n=70) spoke to friends, family and people they used with 
  
                                         
139
 p<0.01 
140
 p<0.05 
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 19% (n=41) sourced information from online forums 
 16% (n=35) had accessed information leaflets 
 16% (n=34) had talked to a drug service 
 16% (n=34) had obtained information on NPS from TV documentaries, and 
 12% (n=27) had sourced information from online social media.  
 
As many participants cited documentaries as a source of information (16%, n=34) 
as speaking to drug service staff (16%, n=34) or sourcing information from leaflets 
accessed in drug services (16%, n=35). 
 
These figures reflect findings from the interviews, where participants stated that 
the main sources of information about NPS were friends or people that 
participants used with (“I had asked him what sort of, you know, what would I feel 
etc”)141, and online forums (“I do a lot of reading online if I was ever going to get 
something”)142.  
 
Leaflets from drug services were also identified in qualitative interviews, although 
this tended to be where people were already engaged with services: 
 
“When I‟m along at the needle exchange I‟ll pick up the leaflets that they‟ve got 
sitting [there].” 141 
 
 
Watching documentaries as a source of information and awareness of NPS harms 
was a theme that also came up in qualitative interviews: 
 
“I watched a documentary on it on [TV programme], I don't know if you've 
ever watched it, but like about four or five times a night paramedics were 
getting called out for folk that were like having a legal high.”143 
 
 
When discussing documentaries, interviewees often focused on the emotional 
impact the stories presented had on them, and the way they prompted them to 
assess their own practice in relation to what they had seen on the screen: 
 
 “I watched this legal highs documentary that was really insightful and I really 
believe that had a lot to do with helping me because there was this couple… I 
was like that girl, and I was watching it with him and he looked like him as 
well, he really looked like him.” 144  
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 Michael, Mental Health Service User 
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 Paula, homeless, mental health service user 
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Documentaries on television were a popular source of information, and one which 
appeared to resonate emotionally with survey participants in a way that other 
forms of information sharing did not.  
 
6.3.2 Providing Information: Service provider knowledge of NPS 
The interviews and focus groups also gave an insight into the views of staff and 
those who had taken NPS about levels of NPS-specific knowledge within drug 
services. Interviews with participants who had taken NPS revealed a strong sense 
that drug services lacked sufficient knowledge of NPS to provide adequate 
information and support.  
 
A typical response was:  
 
“They [drug service] didn‟t know enough about the synthetics [synthetic 
cannabinoids]. They knew bits and pieces maybe about powders and pills 
and they didn‟t know enough about synthetics to help me.” 145  
 
 
Both staff participating in focus groups and interviewees felt that drug services 
overall had less of an understanding of NPS than other, more traditional drugs: 
 
“Traditionally we‟ll say „Heroin: this is the side effects, this is this, this is that, 
this is the withdrawal symptoms…‟ but because there‟s such a plethora of 
different chemicals and changing chemicals, what are you going to do?” 146 
  
 
 
“It‟s just recently everybody seems to [be] taking them [NPS] so they 
[services] probably don‟t ken much about them. The likes of kit [heroin] and 
all that, they sort of know the stages, like what you‟re going to be like if you 
never had the stuff, but with that [NPS] they don‟t really ken [know]” 147 
 
 
This was understood by staff members as stemming from a lack of access to up-
to-date information and training, but, critically, also from the continuously evolving 
nature of NPS: 
 
“The type of NPSs out there, it‟s forever evolving, forever changing and it‟s 
being able to access up to date information”. 148 
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 Kieran, Mental Health Service User 
146
 GGC Focus Group 
147
 Nicola, PWID 
148
 GGC Focus Group 
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Focus group participants expressed concerns about their own lack of knowledge, 
and consequent difficulties in providing reliable information to service users. At the 
same time, NPS survey participants did not see drug services as the only (or 
indeed primary) source of information on NPS. 
 
6.3.3 Providing Support: Client disclosure of NPS Use 
 
Three quarters of surveyed staff across all services reported that they always or 
often asked clients about NPS use when they first presented (75%, n=131). An 
even higher proportion probed for NPS use when asking clients about their drug 
and alcohol use more generally (85%, n=149). Building on this initial contact with 
clients, respondents to the staff survey reported that they were always or often 
likely to enquire about NPS use at routine appointments (60%, n=100), and at 
review meetings (63%, n=105). Within the survey it was not possible to identify 
exactly how workers asked about NPS and it is important to bear in mind that 
there is some confusion among people who use NPS about what is considered a 
NPS149. This should be considered when drawing conclusions about disclosure of 
NPS use. 
 
In focus group discussion, service providers described a reluctance from clients to 
disclose NPS use, and discussed a range of challenges faced in developing and 
delivering services to support people who are experiencing problems related to 
NPS use. Most focus group participants described asking about NPS use directly, 
although some, while doing outreach work, opted for more indirect approaches. 
The key theme that emerged from focus group discussion was the importance of 
asking directly. A shared perception across focus groups was that users rarely 
disclosed their NPS use without being asked:  
 
 “We‟ve actually got to ask that extra question to say do you use NPS or legal 
highs as they would know it? Because if we don‟t they don‟t tell us”.150 
 
 
This is significant given NPS users‟ responses that they did not disclose NPS use 
at drug services. 
 
For staff within most services (social work being a notable exception), direct 
questions provided positive results, with participants across a range of services 
explaining that “I usually just ask them directly and they will just say yes” 151 or that 
“Mine will tell you”.152 When asked directly, outside of social work contexts, many 
people who use NPS appeared happy to disclose their use, but did not routinely 
volunteer that information. The context in which this most frequently occurred was 
as part of a discussion about drug and alcohol use more generally.  
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 SCJS (2016) Scottish Crime and Justice Survey 2014/15: Drug Use. 
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 Lothian Focus Group 
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 GGC Focus Group 
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 Highlands Focus Group 
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6.3.4 Providing support: Client-service user relationships 
 
Again, the interviews and focus group data provided a more detailed insight into 
the views of staff and people who had taken NPS. This suggested that services 
sometimes struggled to support their clients in the context of NPS‟ fast-moving 
nature and consequent lack of easily accessible, up-to-date information for staff. 
Some focus group contributors found that this led to difficulties providing services 
either directly or through signposting. However, others described strategies which 
focused on playing to organisational strengths:  
 
“We‟ve certainly had to adapt our service because of the prevalence of NPS 
and the approach we take is we‟ll use Motivational Interviewing then we‟ll 
look at building a relapse prevention strategy with them, look at other 
supports you can put in place…. With other drugs there is treatment 
pathways that you can go down, whereas for us we‟ve got to rely on the skills 
within the team to try and manage that and get them to take control of it.” 153 
  
 
However, in common with the popularity of documentaries as a source of 
information which resonated in particularly emotional (rather than safety) terms, 
interviewees who made suggestions about how to improve services emphasised 
not particular treatment approaches, but rather the importance of meaningful 
relationships between staff and service users, and spoke highly of individual 
workers (“My worker, she really takes her time and she‟ll get to the bottom of a 
problem”)154 and the importance of ongoing relationships: 
 
”Keeping the same support worker because there‟s nothing worse telling your 
story to one person and getting it changed and having to say it again” 155  
 
 
 “[Support service] was a safe place to go.  But they didn‟t…they couldn‟t 
educate me on the legal highs.  But the people in there were great.  They 
saved my life.”156 
 
 
This is consistent with other research which shows that „alliance‟ (the bond 
between client and therapist) is an important factor in successful therapeutic 
encounters157. 
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6.4 Improving Services  
6.4.1 Service Development: NPS Survey respondent perceptions 
246 of NPS users responded to the question ‘Which one of the following do you 
think is the most important to be offered to NPS users’ (Figure 6.2). 
 
Fig. 6.2: NPS survey respondent opinion on the key area for service development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base: n=246 
 
As illustrated in Figure 6.2 the most popular suggestion for improving services was 
greater provision of detox and rehabilitation services (27%, n=66). This was the 
number one priority across all groups except MSM, who prioritised harm reduction: 
 
 Of the 137 PWID who replied 53 (39%) felt detox/rehabilitation was the most 
important 
 
 Of the 94 people in contact with mental health services who replied 32 
(34%) felt detox/rehabilitation was the most important 
 
 Of the 75 people homeless people who replied 28 (37%) felt 
detox/rehabilitation was the most important 
 
 Of the 38 vulnerable young people who replied 10 (26%) felt 
detox/rehabilitation was the most important, and  
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 Of the 38 MSM who replied 6 (16%) felt detox/rehabilitation was the most 
important.  
 
Dedicated NPS specialist services were welcomed by many: 
 
 Of the 94 people in contact with mental health services who replied, 19 
(20%) felt NPS specialist services were the most important, and 
 
 Of the 75 people homeless people who replied, 14 (19%) felt NPS 
specialist services were the most important. 
 
Harm reduction (e.g. advice and equipment) was popular amongst respondents 
who reported injecting drugs and MSM. This was the case for 27 (20%) of the 
137 PWID who responded to this question and 8 of the 38 (21%) MSM group.  
 
Specialist staff within existing services was also popular amongst some 
respondents who reported injecting drugs and amongst vulnerable young people: 
 
 Of the 137 PWID who replied 14 (10%) felt a specialist within the existing 
service was the most important, and 
 
 Of the 38 vulnerable young people who replied 8 (21%) felt a specialist 
within the existing service was the most important. 
 
The least popular suggestion for improving services was community support (such 
as counselling and mutual aid), with less than 10% of all NPS survey respondents 
identifying it as an effective means to support people affected by NPS use. 
 
6.4.2 Service Development: Staff perceptions 
Respondents to the staff survey reported a range of resources in their services158.  
These included: 
 staff who had basic training in NPS (63%, n=115) 
 one-to-one counselling (48%, n=89), and  
 leaflets (48%, n=88).  
 
This suggests there are some potential areas of mismatch between what people 
who use NPS want and what is currently available or accessible to them. Staff 
reported that in their service, they would like to be able to: 
 refer their clients to a local specialist service (47%, n=87) 
 offer an NPS specialist within the service (45%, n=82)  
 offer leaflets (40%, n=73).  
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This suggests a much stronger overlap between what NPS survey respondents 
consider to be important, notably dedicated specialist services and specialists 
within existing services, and what staff would like to be able to offer. Figure 6.3. 
gives a breakdown of what staff currently offer and would like to offer. 
 
Fig. 6.3: Types of services: staff reports of services currently provided and would like to provide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base: (n=184) 
 
The barriers staff identified to delivering optimal services were primarily: 
 
 Lack of specialist NPS detoxification services (45%, n=83) (overlapping 
strongly with NPS survey suggestions for improving treatment) 
 
 Lack of specialist NPS treatment services (42%, n=78) (again overlapping 
strongly with suggestions made by NPS survey respondents for improving 
treatment), and 
 
 Funding cuts (44%, n=81).  
 
Overstretched resources led one interview respondent feeling under-supported in 
his primary service of choice: 
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“Here at [Sexual health charity] they‟re very stretched. They might have time to 
see me once a week but with bipolar, I‟m sorry with BPD, you‟re all over the place 
and it might strike you in the middle of the night” 159 
 
 
6.4.3 Improving Services: access to information 
Access to up-to-date information emerged as a key theme in both interviews and 
focus groups. One solution proposed by the GGC focus group was the 
development of an app for use by both services and users, which could be easily 
updated:  
 
 
“Participant 1: I think if people are reluctant to come forward and use 
addiction services then they need to focus online for support. Most people 
have got a PC or a tablet or a phone and if it‟s not a traditional kind of group 
of people that would want to access services face-to-face then they need to 
put online resources, whether that‟s education, information, whether it‟s 
forums where people can share their personal experience or a variety of that. 
 
Participant 2: Or an App. 
 
Participant 1: That‟s the way forward. 
 
Participant 2: I think that‟s brilliant, get an App and just do that and they‟re in 
it. That‟s what they need.” 160  
 
 
Suggestions such as this would not only provide a resource for staff and the large 
majority of NPS survey respondents who are not accessing services for their NPS 
use, but also provide information in an easily accessible way. As one young 
person noted in relation to poster campaigns: 
 
 
“The bulk of people I knew that take it [synthetic cannabinoids] were mostly 
always hanging about the town and the only places you see stuff for drugs and 
that are hospitals and community centers and stuff like that, but places we 
hang about like McDonalds and that… there‟s no really that much about there 
that they can get drug advice”. 161  
 
 
These views suggest a need to continue and potentially expand outreach work, as 
well as to explore other new technologies and mediums to engage such as „apps‟, 
and other online resources. However, the NPS survey illustrated that uptake of 
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government-funded online resources such as FRANK and Know the Score was 
low amongst people who had taken NPS. Only 6% (n=13) reported utilising these 
resources, compared to 19% (n=41) who obtained information from online peer-
led forums. Thus while the development of an app or online resource would likely 
be of interest to some people who use NPS, and may be of value to staff working 
with this specific population, it may not attract the numbers that peer-led resources 
do.  
6.5 The Psychoactive Substances Act 
The Psychoactive Substances Act (PSA) scheduled for implementation in April 
2016 came into force on 26 May 2016, after all interviews and focus groups had 
been conducted and the survey period was nearly complete. Therefore, the 
qualitative data and majority of survey responses are from a perspective of 
anticipated change.  
 
6.5.1 Introduction of PSA: NPS Survey Respondent Perspectives 
As outlined in Chapter 4, knowledge of the legal status of specific substances was 
not consistent, and 6% (n=26) of NPS survey participants stated that they did not 
know if they took NPS or not. Similarly, many interviewees appeared unaware of 
the then-forthcoming PSA: 
 
Interviewer: There's a ban coming in, in April.  
 
“Peter: Ooft, I don't believe that man, it only took them about 4 year…. I think 
that's an amazing idea.” 162  
 
 
Or unclear about what it would mean: 
 
Interviewer: Do you know much about the ban that‟s coming in?  
  
“Tiffany: All I know is that there‟s a blanket ban on all legal highs, whatever 
that means, I don‟t know” 163.  
 
 
Any discussion of views on the impact of the legislation must therefore be 
caveated with an acknowledgement that not all participants were fully aware of 
issues surrounding legality of NPS. 
 
249 NPS users provided information on how the PSA might impact on their 
personal NPS use. Over half of NPS survey participants (57%, n=141) reported 
that the legislation would have no impact. This opinion was consistent across all 
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groups but was highest amongst MSM respondents, with three quarters expecting 
the PSA to have no impact (74%, n=28)164.  
 
However of the 249 people who responded to the question on possible impact, 
others anticipated that in terms of their personal use they would: 
 
 move or return to using traditional drugs (29%, n=73)  
 buy from a dealer (21%, n=52). 
 
A further 7% (n=17) thought that they would try something else.  Only 6% (n=15) 
thought that they would stop using NPS altogether165. 
 
Despite low levels of people reporting their expectations of stopping NPS use, the 
ban was eagerly anticipated by some in the interviews (“I‟m just hanging on „til 
April [2016, then expected start of the ban]. Once that‟s out the shops, I don‟t 
know anybody I can go to”)166. 
 
Other anticipated effects of the PSA related to availability (see Fig.6.4).  
 
248 NPS users responded to a question on where they sourced NPS: 
 
 45% (n=112) reported purchasing from shops   
 37% (n=91) reported purchasing from dealers 
 34% (n=83) reported purchasing  from friends or family, and  
 14% (n=34) purchased NPS online.  
 
The primacy of shops as a source of NPS was consistent across groups, with 
MSM buying from shops at a slightly lower rate (43%, n=13), compared with 
people who inject drugs buying from shops at a slightly higher rate (48%, n=67, 
compared to the average of 45%).167 
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Fig.6.4: Source of NPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base (n=248) 
 
 
One consequence of the PSA having now come into effect is that it is an offence 
for shops to sell NPS168. Many areas of Scotland had already instigated headshop 
closures locally through Trading Standards action at the time of data collection. 
41% (n=75) of staff surveyed reported that this had already occurred in their area, 
but a further 37% (n=68) did not know the current status of headshops locally.  
 
When asked about the impact of the PSA on sourcing NPS, 21% (n=52) thought 
they would buy NPS from a dealer, and 7% (n=18) thought they would buy NPS 
online. Buying from a dealer was highest among homeless people (33%, n=25)169 
A potential risk of this was highlighted in interviews with regards to purity: 
 
“When the ban comes in, I mean people are going to sell you anything and tell 
you it‟s legal highs and you‟re not going to know any difference” 170 
 
 
This suggests that based on anticipated future behaviour, vulnerable groups who 
take NPS are more likely to continue to use NPS and source either from dealers or 
directly online than stop use.  This entails some risks for people who use NPS: 
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“How would you regulate that…? Well it will just go underground then. It‟s got 
to. Prohibition, know what I mean? Come on. Then it would be dangerous. 
Think about it. I‟m saying this to the Scottish Government, here and now, if 
you‟re going to ban these then it‟s going to go underground and it‟s going to 
get even more dangerous than it is the now.” 171   
 
 
6.5.2 Introduction of PSA: Staff views 
The staff responses shared some similar themes with NPS survey responses.  
Around half of staff who responded to the survey anticipated that their clients 
would continue to take NPS (56%, n=103), but would shift to sourcing via dealers 
(35%, n=64), and online (49%, n=91). However, a much higher proportion (46%, 
n=84), thought clients would return to using traditional drugs.  
 
A final consequence of the PSA coming into effect, and potentially driving NPS 
use underground, was raised:  
 
 
“It‟s hard enough now to get a disclosure, you know, and to maybe put some 
support in place is going to be worse, people will not disclose, you know and it 
could become more problematic by the time it comes to that. I don‟t think it‟s 
going to work.” 172 
 
 
As discussed earlier disclosure was already felt by many staff to be a challenge to 
service delivery and one which some felt risked becoming even more difficult after 
the PSA came into effect.  
6.6 Discussion 
Rates of contact regarding NPS use were particularly low, indicating that people 
who are using drug treatment and other services, are not talking to these services 
about their NPS use.   
 
Low levels of contact with social work, mutual aid, and drug, homeless, mental 
and sexual health services were reported. Use of ambulance and A&E services 
related to NPS use was considerably higher, particularly among people who inject 
drugs. It should also be noted that 36% (n=69) of NPS users who answered 
treatment related questions were not in contact with drug services at all. 
 
The low levels of contact with services for NPS suggests that there is a need not 
only to raise the profile of available NPS support within services, and to work to 
develop that support, but also to ensure that staff are adequately trained to ask 
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about and respond to NPS use.  This should include staff working in emergency 
care given the rates of NPS users that reported presenting at emergency 
departments.  As identified in the staff focus groups, asking directly about NPS 
use was important, and may involve reviewing standard assessment paperwork 
and procedures, which often ask about NPS use as part of a drug history. A desire 
for specialist treatment responses was highlighted by both NPS and staff survey 
respondents. What those services could look like and what adaptions could be 
made to existing services may be useful to explore. 
 
Sources of information and the fast-changing nature of NPS highlighted 
information needs for both staff and NPS users. There is already a cohort of 
people who use NPS who derive significant value from providing clear, detailed 
accounts of use to facilitate safe use among others173. Such a population of users 
represent a potential resource for others and demonstrate a peer education model 
that could be applied for other groups. Leaflets were as popular a source of 
information as talking to staff, and also popular were documentaries, which 
highlighted that a range of information forms could be useful for different groups. 
Research conducted by drug charity Lifeline into awareness campaigns, found 
that use of film in the form of cartoons was highlighted by service users as a 
potential way of reaching people including vulnerable young people and those with 
literacy barriers.174  
 
Some services struggled around providing effective NPS specific treatment 
options, and focused on existing approaches such as Motivational Interviewing. 
Interviewees who had taken NPS, by contrast, did not express views on this but 
rather emphasised the importance of continuity of care between service user and 
service provider and the impact of individual key workers. This is confirmed by 
other studies, which find appropriate treatment, and finding staff motivating, are a 
key element in satisfaction with treatment by service users.175 
 
Finally, NPS and staff survey respondents articulated broadly similar views on the 
impact of the Psychoactive Substances Act. Both groups saw NPS users shifting 
back to or towards traditional drug use, and among those who maintained NPS 
use, a shift from purchasing via shop to purchasing via dealers. Few NPS survey 
respondents anticipated moving to buying online, which is in contrast to what 
might be expected from recent research into drug purchases on the dark net176 or 
staff expectations. Many of the participants here were unstably accommodated 
and therefore most likely lacking Internet access to successfully navigate online 
drug purchases.  
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Online drug markets often rely on buyer feedback to rate vendors, ensuring an 
overall emphasis on quality and purity177 to maintain good vendor reputation. This 
eBay-like approach is not adopted in street sales, where buyers are much more 
vulnerable to the inclusion of impurities in or „cutting‟ of the substances purchased, 
and even the substance purchased not being what they expected to buy178. This 
could be a significant consequence of the shift from purchasing primarily via shops 
to dealers amongst the populations discussed here.  
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7. Discussions and conclusions 
 
This study builds our understanding of the use of NPS amongst key vulnerable 
groups in Scotland.  Based on the findings in this study, this section outlines a 
number of key learning points for further discussion and consideration. 
 
7.1 Prevalence 
 
Key learning point 1: 
 Database tools such as DAISy should be adapted and in the case of needle 
exchange data collection, standardised, to include specific questions 
relating to NPS use, this may include individual NPS names or categories.  
Training for frontline workers in how best to apply these tools should be 
incorporated in this process. 
 
The findings from this research suggest use amongst vulnerable populations is 
likely to be far higher than in the general population, where NPS use is relatively 
low, although somewhat higher amongst young people.179,180 However, vulnerable 
young people and MSM were the more challenging groups to engage in this study. 
Additionally, access to some rural areas was limited. In order to develop a more 
detailed picture of NPS use in Scotland, more focused exploration of specific 
issues within these target groups and regions may be required. 
In order to develop robust estimates of NPS use there needs to be an 
improvement in data collection within services.  The new database for drug and 
alcohol services currently being developed (Drug and Alcohol Integrated System – 
DAISy) provides an opportunity to collect reliable data provided staff are enabled 
to undertake thorough initial assessments.  Similarly needle exchange data has 
the potential to provide useful prevalence data, again provided staff are 
appropriately equipped to encourage accurate disclosure of NPS use. 
Any training on data collection tools should focus on how accurate and reliable 
information can be collected either at initial assessment or subsequently. Part of 
this will involve reassuring services users that honest responses will not hinder 
their access to certain services and that honest answers will help ensure the 
appropriate care package is put together.  
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7.2 Motives for use 
 
Key learning point 2: 
 Motives for use should be identified in assessments and reviews with 
service users and used to inform care plans undertaken by support services 
and frontline staff. 
 
 
This research highlighted that the motives for NPS use varied across the different 
types of NPS, although it was clear that ease of access, price, curiosity and 
pleasure were common drivers. This is similar to findings from other literature such 
as Global Drug Survey.181 
A better understanding of these motives for NPS use and how they may vary 
based on population groups and NPS type can help to inform interventions by 
services. In particular, there may be benefits to targeted interventions for people 
who intend to continue using, reduce use and for those who wish to stop using. 
Approaches such as Motivational Interviewing already include offering clients a 
menu of options, which would take account of the different goals NPS users may 
have.182 
Perception of harms and health benefits and how these related to motives for 
using are also useful to consider.  For example, use of benzodiazepine-type NPS 
and experiencing sleep benefits may suggest a particular need to address 
possible motives such as self-medication. 
It was also notable that legal status did not appear to be a key motive for use 
within this study; this is again in line with findings by the Global Drug Survey.183 
Taken alongside the findings from Chapter 6, which showed that the majority of 
respondents to the NPS survey did not anticipate the Act impacting on their NPS 
use, this suggests that NPS are likely to continue to be a feature of substance use 
patterns amongst these vulnerable groups. 
 
7.3 Consequences of use 
 
Although some positive consequences for use were identified, harms for NPS use 
shared similar themes to other existing literature, which identifies a range of 
mental health, physical health and social harms.184 
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Mental health harms 
 
Key learning point 3: 
 Greater partnership working between substance use and mental health 
services and a review of care pathways for those with substance use and 
mental health difficulties should be considered. 
 
 
Harms to mental health were the most commonly reported consequences of NPS 
use, and have been the subject of recent research on acute hospital 
admissions.185 With a high proportion of NPS survey respondents in contact with 
mental health services either currently or in the past, the risks of further 
exacerbating mental health problems are high and need to be considered within 
any treatment settings where people are likely to be presenting with both 
substance use and mental health difficulties. Better collaboration and partnership 
working between mental health services and drug services will assist in better care 
of this population. 
Furthermore, use of NPS to manage mental health, particularly anxiety, emerged 
in relation to those using benzodiazepines-type NPS, which may suggest escape 
coping, or long-term, non-medically supervised use.  This highlights the need to 
better understand the relationship between NPS use and mental health and a 
potential need for a dedicated treatment response to sustained self-prescribed 
benzodiazepine use and anxiety. All these areas present a need to develop the 
care pathways for people with substance use and mental health difficulties.  
 
Physical health harms 
 
 
Key learning point 4: 
 Assessments within key services should ensure they cover a range of 
physical health areas including sleep management. 
 
 
Sleep problems were one of the most commonly reported physical harms across 
all NPS.  However, people who had taken synthetic cannabinoids and 
benzodiazepine-type NPS also reported positive, sleep-promoting effects of use. 
This outlines a challenge for treatment providers in motivating service users to 
address substance use where it is used to facilitate sleep.  Other studies have 
shown the correlation between sleep and drug use in that sleep problems can be a 
trigger for drug use and vice versa.186  Many treatment services offer support and 
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advice around sleep hygiene as part of a treatment plan, however services often 
report that there are limited resources and in-house expertise in this area. Whilst 
specialist clinics exist for sleep, these are rarely available to people who use NPS 
or indeed other drugs generally unless they meet specific criteria for sleep 
problems which is separate to their drug use. Accessing dedicated sleep clinics 
would generally be restricted to people further into recovery given the likelihood 
that drug use is affecting the sleep problem. The findings in this study suggest that 
there could be benefits to offering sleep management support earlier to those 
currently using NPS as a way of trying to deal with their sleep problems which may 
in turn allow them to stop or reduce substance use.  Training for support staff and 
dedicated group work or clinics and drug specific literature for people who use 
NPS and are experiencing sleep problems may be of benefit to both educate and 
guide treatment options for service users. 
Loss of co-ordination was another commonly reported physical harm for some 
types of NPS and highlights a possible greater risk of accidents when under the 
influence. Seizures and effects on heart rate as identified by some NPS users in 
this study are also identified in other literature with additional physical harms 
including cardiovascular, lung and kidney problems.187  Given that a substantial 
proportion of NPS users report not disclosing NPS use, assessments within key 
services which cover a range of health areas could assist in opening up a dialogue 
regarding NPS use and related harms and encourage better disclosure of NPS 
use. 
 
Social harms 
 
 
Key learning point 5: 
 Multi-agency and flexible working approaches such as assertive outreach 
should be continued and developed to support people with the range of 
social harms experienced. 
 
 
Debt, loss of tenancy and anti-social behavior (which could lead to loss of 
tenancy) were key harms identified by people who use NPS in this sample, with 
22% (n=92) of the NPS survey respondents identifying as already homeless.  This 
highlights the need to include financial and housing support for people who use 
NPS in the range of services offered. 
 
Given the issue of missed appointments identified in this sample, it is perhaps not 
surprising that over one third of people who used NPS reported not being in 
contact with drug services (although this could also be a consequence of the way 
the sample was recruited). Non-engagement is often a key issue faced by 
services, and services which are able to provide flexibility in supporting clients 
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such as assertive outreach, longer opening hours, appointment reminder systems 
or drop in sessions often report higher rates of engagement from vulnerable 
populations.188 Equally, with regards to benefit sanctions, greater awareness of 
the complexities of problem drug use and the impact of sanctions on these 
vulnerable groups would be advantageous. Research has identified hardship 
caused by benefit sanctions in Glasgow including rent arrears, sometimes leading 
to eviction.189 
 
This constellation of harms – loss of tenancies, missed appointments and benefit 
sanctions – will undoubtedly lead to a proportion of the population studied being 
particularly vulnerable.  How this group is protected from further harm should be 
considered by local planners and services. As identified in more detail in treatment 
responses and improving practice, multi-agency responses and training for staff 
required to work with a range of complex issues would be beneficial in ensuring 
people get the interventions required to reduce harms. 
 
7.4 Improving practice 
 
Key learning point 6: 
 Provision of basic NPS training for all staff and training in a variety of health 
based topics and assessment for support staff should be considered by 
frontline services.  
 
The low levels of NPS users reporting NPS use to the existing treatment providers 
they are in contact with, and the challenges outlined by frontline staff in keeping up 
to date, highlights a need for staff to have current knowledge of NPS. Workforce 
development may benefit from a systems approach, which could involve not only 
training, but also addressing and embedding NPS in existing workforce 
development strategies and ensuring adequate support and supervision is 
provided for staff working with NPS. A minimum requirement in terms of improving 
practice is the provision of basic NPS training for all staff, and updates on new 
NPS trends. As this study identified, NPS are most often used in combination with 
traditional drugs, and up-to-date training on general drug awareness and poly-
substance use is likely to be beneficial for front line services.  Given that staff 
identified lack of specialist treatment as a barrier to service utilisation for people 
who use NPS, more comprehensive training on NPS would be recommended for 
more specialist services, especially for those services currently or hoping to offer 
treatment to people who use NPS. 
With significant crossover within the vulnerable populations, in particular homeless 
people, injecting drug users and people in contact with mental health services, and 
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the range of issues articulated by people who use NPS in this sample, training in 
complementary topics such as mental health, sexual health, chemsex, 
homelessness, and sleep hygiene in addition to drug awareness would contribute 
to the development of holistic NPS services.  Training in assessment would also 
assist in being able to identify NPS use and related harms.  
 
7.5 Service developments 
 
Key learning point 7: 
 Health board and ADP areas should review possibilities for service 
developments or adaptations to existing services to respond to NPS users. 
 
People who use NPS and frontline staff both identified the provision of specialist 
treatment for NPS as an important area for improving services. In particular, 
residential detoxification and rehabilitation were desired services among people 
who use NPS. This was stated particularly by people who inject drugs, homeless 
people and people in contact with mental health services, over one third of whom 
identified residential detox and rehabilitation as an important treatment option. 
Over a quarter of vulnerable young people identified residential detox and 
rehabilitation as a treatment need. This suggests a role for Child and Adolescent 
Mental Health Services (CAMHS) and youth addiction services to explore how 
best to provide more targeted services for this population.  
Although provision of NPS specialist residential detox and rehabilitation is likely to 
be unrealistic in the current funding climate, existing treatment centers could be 
utilised to provide NPS detox options. The most likely NPS to require inpatient 
detox would be with benzodiazepine-type NPS. Although the expertise for offering 
general benzodiazepine treatment already exists there are challenges in 
accessing this level of treatment due to reduced funding for residential services. 
Clinical guidelines have recently been developed which outline how to respond to 
acute harms and advise on detoxification.190  
 
NPS specialist staff, whether in existing services or specialist services were seen 
by both people who use NPS and staff to be a valuable asset to be developed. 
With limited resource for specialist services, the development and expansion of 
the remit of established treatment services including dedicated workers within 
existing services could be useful to explore. Adapting current treatment services to 
offer residential detox and rehabilitation for NPS users as outlined above would be 
a cost effective response to NPS use in Scotland. 
 
MSM had low levels of contact, and did not present with the same level of multiple 
vulnerabilities as other groups. They also favoured harm reduction over other 
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treatments. This highlights merit in considering the rebranding of services to 
appeal to „new‟ service users, perhaps considering moving away from the more 
traditional branding of drug services such as addiction services or drug problem 
services and utilising targeted resources and adverts to reach out to particular 
populations e.g. MSM- and vulnerable young person-specific. Opening hours 
could be a further consideration with certain aspects of the NPS treatment 
populations perhaps struggling to access services within the working day hours 
often offered by services. Evenings and weekends opening could be attractive to 
vulnerable young people and MSM in particular. Guidance on substance use 
services responding to MSM recommends the importance of services being 
available outside normal working hours and highlights example service models 
including, satellite services or outreach services operating in targeted areas. 191 
Local scoping exercises gaining the views of people who use services and people 
who would potentially use services would be useful in establishing evidence for 
these options and would also take account of likely regional varieties. 
 
The findings from this research also suggest that services should consider 
developing the skills and expertise of one member of staff who can keep up to 
date with new developments and provide advice and assistance to other staff. 
Services have utilised a dedicated worker model for other aspects of treatment 
often in combination with utilising people with lived experience192 such as in the 
mental health or recovery specific services, therefore it would be possible to build 
on this to develop a similar system of named NPS workers hosted within services. 
It would be crucial to ensure such workers had the appropriate skills, knowledge 
and training for these roles, and that the services had appropriate resources to 
maintain and develop this knowledge. As outlined in this study there is still an 
information gap in some areas when it comes to NPS resources and basic NPS 
training. In order for staff to take on a specialist worker role, a higher level of NPS 
training would also be beneficial to ensure service quality. 
 
 
7.6 Engaging vulnerable populations 
 
Key learning point 8: 
 Multi agency and targeted responses should be explored for the different 
populations using NPS. 
 
 
There was considerable cross over between the populations of homeless people, 
mental health service users and people who inject drugs. This highlights that NPS 
users often face a range of issues including ill health, homelessness and financial 
problems.  Multi-agency responses are effective for those groups experiencing 
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multiple disadvantages and have been recommended by services responding to 
„club drugs‟ and NPS.193  The population-specific harms identified in Chapter 5, 
and the low levels of engagement with services amongst MSM who responded to 
the NPS survey suggest that there is a need for specific service developments 
within key services that MSM are likely to use. This may include sexual health 
services and targeted gay men‟s health provision where it exists.  Similarly, 
services for vulnerable young people should explore how best to address NPS 
and wider substance use among their young people. 
Hosting dedicated drug workers within partner organisations including sexual 
health, mental health and/or emergency care could effectively capture those 
people who are not in regular drug treatment and may be at greater likelihood of 
using other services and/or emergency care.  This model has been utilised to 
great success in other parts of the UK such as 56 Dean Street in London which 
houses sexual health and drugs workers within the service aimed at MSM. 
With the majority of NPS survey respondents sourcing information from peers 
combined with low levels of service contact for NPS use, this may suggest 
assertive outreach combined with use of peer support could be worthy of 
exploration. There are various existing models which couple peer support with 
harm reduction such as the stepped care model used by Crew in Edinburgh or 
with abstinence based treatment as underpins the therapeutic community model 
offered by Phoenix Futures Scotland. 
Tailored care and relationships with support staff were both identified by NPS 
users as important, which is confirmed by other studies.194 Findings from specialist 
services suggest treatment is more likely to be accessed by people who would not 
otherwise seek treatment if it is appropriate to their needs.195 
 
7.7 Information on NPS to people who use NPS 
 
Key learning point 9: 
 Information resources in a variety of formats are required to reach the 
different populations who use NPS. 
 
Both NPS and staff survey respondents highlighted information needs. With 
around a third of NPS survey respondents sourcing information from peers, and 
40% of staff identifying dedicated NPS resources such as leaflets as being 
something they would like to offer, there is potential to look at leaflet resources for 
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the different target populations. Additional and targeted resources could build on 
the Know the Score resource aimed at young people, which would be more 
accessible and marketable to vulnerable populations.   
Consideration of new formats for sharing information including „apps‟ may also be 
of benefit for certain populations in order to make information more accessible.  
NHS Tayside currently provide the Cool2talk service which utilises an online portal 
to inform young people about a range of health issues including drugs.  Equally, 
film resources specific to NPS may be of benefit for populations who may not be 
able to access traditional mediums such as leaflets and where demonstration 
elements would be useful in preventing BBV harms such as safer injecting. With 
people who use NPS citing documentaries as a source of information, and use of 
resources such as cartoons196 piloted by other treatment providers such as 
Lifeline, there is an opportunity to explore use of film media as a resource to reach 
NPS using groups. Use of film has been piloted in the prison population for NPS in 
Scotland but a more formal pilot with evaluation of effectiveness would be required 
to gauge the usefulness of this approach.197 
 
 
7.8 Psychoactive Substances Act 
 
Key learning point 10: 
 Monitoring of the impact of the PSA on vulnerable populations should be 
undertaken by ADPs, health boards and services with a particular focus on 
increased overdose risk. 
 
The Psychoactive Substances Act (PSA) came into effect during survey data 
collection on 26th May 2016. Unintended consequences of the PSA were 
anticipated by study participants to include diverted modes of purchase to more 
underground means, and returning or transitioning to traditional drug use. 
Therefore there is potential for increased harms for some people who use NPS 
related to adulterants in street purchases and a possible need for greater 
resources and funding in both treatment and criminal justice settings to respond to 
emerging developments, such as around access and criminality, following on from 
enforcement of the Psychoactive Substances Act.  
It will be important to track the impact of the PSA particularly regarding the impact 
of changes in supply routes of NPS that might have particular impacts on 
vulnerable populations who use NPS.  
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Transitioning back to traditional drug use was flagged up by respondents in both 
surveys as an anticipated outcome of the PSA coming into force. It was further 
flagged up in focus groups in relation to opiate users moving back from NPS use 
(in particular mephedrone and ethylphenidate) to heroin use. For those people 
who use both NPS and heroin and other opioids, the risks of transitioning back to 
use or heavier use of heroin is high, especially where access to NPS may be more 
difficult either through availability or increased price. With overdose risk increasing 
significantly where people may have a reduced tolerance for opioids, provision of 
Naloxone is a crucial part of the treatment response. Alcohol and Drug 
Partnerships and Naloxone co-ordinators should be alerted to the potential for 
increased overdose risk so that appropriate action can be taken, including supply 
of Naloxone to vulnerable populations. In addition to Naloxone provision, an 
effective response may involve an element of staff training in order to raise 
awareness in non-drug specialist settings.  
 
 
7.9 Study limitations  
This study builds our understanding of the use of NPS amongst key vulnerable 
groups.  The size of the sample is not large enough to draw final conclusions 
about NPS use in Scotland.  Vulnerable young people and MSM were the more 
challenging groups to engage in this study and had the smallest sample sizes, 
additionally access to some rural areas was limited so the findings of this study 
may not be representative. In terms of use in the general population, this study 
cannot give an indication of this as it focused solely on vulnerable groups.  
Estimating prevalence of NPS use amongst vulnerable populations was not 
possible, due to the under-reporting of NPS use by vulnerable populations to 
services, combined with limited existing data within services and availability of 
national data sets effectively capturing NPS use.  What the study does provide is 
an insight into patterns of use amongst vulnerable groups, including motives and 
consequences of use in the Scottish context. 
Given the challenges of gathering robust data on the prevalence of „traditional‟ 
drug use, a focus on harms and motivations amongst specific populations would 
likely be the most useful focus for further research in developing more effective 
prevention and treatment responses. 
Similarly to other data sets in Scotland, this study relied on self-reported data. 
Given the confusion of what constitutes an NPS, this may have affected who 
opted in or out of the study.  
This study extends our knowledge of some of the potential harms experienced 
from NPS use, although it should be acknowledged that given the high rates of 
poly-drug use within this sample, exact causation of harms cannot be determined.   
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With the implementation of the Psychoactive Substances Act coming in during the 
study, responses on the forthcoming ban were anticipatory rather than 
experiential. 
 
7.10 Closing remarks 
NPS use amongst these groups is complex and results in a number of harms and 
specific treatment needs. This research is important because but it provides a 
tentative first understanding of patterns of NPS use, alongside motives and 
consequences of use amongst vulnerable groups in Scotland.    
With many factors likely to influence trends within NPS in Scotland, including the 
PSA, which came into force during data collection, more information is needed to 
gather a fuller picture of the emerging NPS landscape in Scotland.  
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Appendices 
 
A. Technical Appendix 1: NEO Data 
Estimating the number of injecting NPS takers by applying statistical models 
for incomplete count data to needle exchange data 
 
As part of this study possible sources of administrative data relating to NPS use 
that could be used to estimate the prevalence of NPS use in Scotland were 
examined. When estimating the prevalence of opiate use mark re-capture 
methods have been used with some success in Scotland and England but these 
require data from a number of different sources and detailed information at the 
individual level. Sufficient numbers of NPS takers are not currently appearing in 
these data sources to make this multi-source method an option but researchers 
have met with some success using single source estimation methods for areas 
with sparse data or only one available data set (Hay & Smit, 2003). With this in 
mind the research team approached NHS Greater Glasgow and Clyde and NHS 
Lothian with a view to obtaining data from their Neo 3600 database and assessing 
the feasibility of using this data to produce estimates of injecting NPS use for 
these two areas. The following section describes the needle exchange data used 
in the analysis and gives the resultant estimates of injecting NPS use for NHS 
Greater Glasgow and Clyde and NHS Lothian areas. 
 
Methods 
The method used to produce population estimates from a single data set is known 
as truncated Poisson. In our case we will be examining the number of visitors to 
needle exchange services over a 12-month period. When applying this method, 
we note the frequency for visits for every individual over the duration of the study. 
The frequency pattern follows a Poisson distribution but our data is incomplete as 
we cannot observe individuals that appear zero times, therefore the distribution is 
truncated below one. An estimate of the total population is given by adding all 
observed individuals to an estimate of those that appear zero times, the hidden 
population. As part of our analysis we have used two different estimators, the 
Zelterman (1988) and Chao estimators (1998). Both estimators can be calculated 
using the total number of individuals along with the lower case frequencies and 
given their simplicity the formulae are given below. 
 
Zelterman‟s estimator of the unknown population size est(N) is given by: 
 
est(N)  = n/ [1 – Probability(f0)] 
 
Where the Probability (f0) is e
λ 
 
 λ =  2 * (f2/f1) 
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Chao‟s estimator is given by: 
 
   est(N) = n +     ( f1) 
2 
                  
                  2(f2)  
 
where, 
 f1 = the number of individuals appearing just once in the data set 
 f2 = the number of individuals appearing twice in the data set 
 n = all individuals appearing in the data set 
 
Both estimators are based on the lower frequencies, as it is thought that those that 
are observed only once or twice in a data set resemble closely those that do not 
appear in the data set at all. This dependence on the lower frequencies is also 
helpful when addressing some possible heterogeneity in the data set as those that 
appear a huge number of times may not reflect the „typical‟ service user so a 
greater reliance on the earlier frequency classes lessens the impact of these 
groups. It should be borne in mind that if the frequency patterns for NPS users 
differ greatly from this description then this could impact on the estimates. Another 
positive aspect of the method is its ability to cope with sparse data. As with all 
estimation methods there are certain assumptions that must be met. These are: 
 
1. the population is „closed‟ 
2. the population is homogeneous (no heterogeneity across individuals) 
3. the individual probabilities of observation and re-observation are stable over 
time. 
 
Closed population 
The closed population assumption stresses that the true population is unaffected 
by births, deaths or migrations over the study period. In order to minimise the 
potential for this assumption to be violated we have chosen to use a slice of data 
covering a 12 month period. 
 
Homogeneous population 
This assumption asserts that the probability of observation should not differ greatly 
across groups of individuals. Both estimators used are robust in relation to 
heterogeneity and are known to underestimate the true population. In order to 
assess any heterogeneity we have attempted to stratify the estimates by gender 
and/or age group where the data was available. This will help us to model any 
heterogeneity in relation to these characteristics. 
 
Stable (re)capture probability 
This assumption would mean that attending the needle exchange on one occasion 
wouldn‟t necessarily impact the probability of future attendance. In order to lessen 
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the impact of violating this assumption we have confined the data slice to a short 
12-month period. 
 
Data 
Data is routinely collected from pharmacies/needle exchange services and 
entered into Neo 3600 database. Although the data is collated from a number of 
different sources around both health board areas, as it is collated to health board 
level in this database, we treat it as a single source.  Every service user is 
assigned a unique identifier composed of initials and date of birth, given the 
sensitive nature of this data the reference code was „blurred‟ before passing to 
research team so that we could identify unique individuals without having access 
to these identifiers.  
 
Data and estimates for NHS Greater Glasgow and Clyde area 
There were 1,896 transactions by NPS takers at NHS Greater Glasgow & Clyde 
needle exchange services between 01/01/15 and 31/12/15. This data corresponds 
to 148 individuals. Twelve individuals were from outside the NHS GGC area and 
so were removed from the analysis. The remaining sample were overwhelming 
male (88%) and ranging in age from 18 to 61 with a mean age of 38. Over half 
(56%) of the NPS takers accessing needle exchange services in the NHS GGC 
area are poly drug users with 43% reporting using heroin. When asked if they 
were in structured treatment for their drug use only 131 individuals responded with 
twenty-one (6%) confirming that they were in structured treatment. Table 1 shows 
the frequency data required to produce estimates of the hidden population of 
injecting NPS takers.  
 
Table 1: Frequency of contact at Greater Glasgow & Clyde needle exchange services by gender 
 All individuals in 
data set 
Individuals 
appearing once 
Individuals 
appearing twice 
Male 120 22 14 
Female 16 5 3 
Total 136 27 17 
 
Table 2 lists the estimates of injecting NPS takers. There are two estimates 
relating to each estimator, the unstratified estimate and an estimate stratified by 
gender. The Zelterman estimator produces a figure of 190 injecting NPS takers. 
The direct, unstratified estimate is the same as the sum of the stratified gender 
estimates. We can see that the stratified estimates have a slightly wider 
confidence interval running from 114-265. The lower bound of this confidence 
interval is lower than the total number of observed individuals which indicates that 
the observed number of women was too small for the asymptotic estimation of the 
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95% confidence intervals. As we would anticipate the Zelterman estimates are 
slightly higher than those produced by the Chao estimator which gives an estimate 
of 157 injecting NPS users. Again the sum of the stratified or pooled gender 
estimate is the same as the unstratified estimate but for the Chao estimator the 
confident intervals are narrower than those for the Zelterman estimates. It should 
be noted that the 95% confidence intervals overlap for both sets of estimates.  
 
Table 2: Population size estimates for injecting NPS takers in NHS Greater Glasgow & Clyde 
area using Zelterman‟s (1988) and Chao‟s (1989) estimators 
 n Est (N) 95% CI 
Hidden 
population 
Known/ 
Hidden 
Zelterman‟s unstratified estimate 136 190 130-250 54 2.52 
Zelterman‟s stratified estimate (gender) 136 190 114-265 54 2.52 
Chao‟s unstratified estimate 136 157 144-190 21 6.48 
Chao‟s stratified estimate (gender) 136 157 143-210 21 6.48 
 
Data and estimates for NHS Lothian area 
There were 7,717 visits by injecting NPS takers to needle exchange services in 
the NHS Lothian area between 01/01/15 and 31/12/15. These visits were made by 
447 individuals. Seven users were from outside the NHS Lothian area and were 
removed from the analysis to leave a final sample of 440 individuals. The majority 
of users visiting needle exchanges during this period were male (79%) and aged 
between 18 and 60, with a mean age of 35. Housing status was recorded for 320 
of the sample and just over half owned or rented their accommodation, 41% were 
in temporary accommodation, the remainder were sleeping rough (6%). When 
asked about accessing structured treatment only 194 (44%) responded with 25% 
indicating they attend a specialist drug treatment service and a further 21% 
receive support from their GP.  
 
Table 3: Frequency of contact at Lothian needle exchange services by gender & age group 
 All individuals 
in data set 
Individuals appearing 
once 
Individuals appearing 
twice 
Male 349 77 37 
Female 91 14 13 
18 – 24 14 7 2 
25 – 34 202 38 26 
35 – 64 224 46 22 
Total 440 91 50 
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Table 3 lists the number of individuals visiting NHS Lothian needle exchanges by 
gender and age group. As stated previously the majority of users are male. There 
are few injecting NPS takers under the age of 25 attending needle exchanges. 
Table 4 lists the estimates of injecting NPS takers for both the Zelterman and 
Chao estimators with corresponding confidence intervals. There are three 
estimates given for each method, the unstratified estimate plus gender and age 
stratifications.  
 
Table 4: Population size estimates for injecting NPS takers in NHS Lothian area using 
Zelterman‟s (1988) and Chao‟s (1989) estimators 
 
n Est (N) 95% CI 
Hidden 
population 
Known/ 
Hidden 
Zelterman‟s unstratified estimate 440 660 572-748 220 2.00 
Zelterman‟s stratified estimate 
(gender) 
440 673 562-784 233 1.89 
Zelterman‟s stratified estimate (age 
group) 
440 667 527-807 227 1.94 
Chao‟s unstratified estimate 440 523 457-842 83 5.30 
Chao‟s stratified estimate (gender) 440 528 454-994 88 5.00 
Chao‟s stratified estimate (age group) 440 528 450-1357 84 5.24 
 
The unstratified Zelterman estimate gives a similar if slightly lower result than both 
the stratified gender and age estimates. This would be expected as the unstratified 
estimate is considered an underestimate and the stratified estimates attempt to 
model any heterogeneity in the sample resulting in a larger estimate. As 
anticipated the Chao estimates are lower than those produced by the Zelterman 
estimator, however the age group estimate has a wider confidence interval 
indicating some uncertainty in the model. When the separate stratified estimates 
are examined this occurs in the older age group (35-64). 
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B. Technical Appendix 2: Prevalence estimate 
 
Estimating the prevalence of NPS use in Scotland using a treatment 
multiplier 
 
The multiplier method is a simple way of estimating unknown populations such as 
prevalence of drug use. The method uses the available information on the 
population in question as a benchmark, e.g. number of drug users in treatment, 
and applies a multiplier that is related to the population and has normally been 
derived from a small scale study. 
 
Construction of the treatment multiplier 
 
From our survey we know that 125 NPS users are in contact with drug treatment 
services. Only 194 NPS survey participants answered this question giving us a 
treatment rate of 64.43%. Therefore we can say that for every 1 NPS user in 
treatment there are 1.56 users (100/64.43). 
 
Using the treatment multiplier to produce an estimate for the number of NPS 
users in Scotland 
 
We sought data on the numbers of NPS users in treatment from the Scottish Drug 
Misuse Database. The data dashboard‟s latest available update in May 2016 gives 
treatment numbers for 2014/15. This data set does not currently provide detailed 
information on NPS use. For the year 2014/15, they reported 191 people in 
Scotland receiving treatment for Mephedrone use and a further 636 receiving 
treatment for use of „other‟ drugs. This gives us a total of 827 users in treatment. 
Using the multiplier, this would generate an estimate of 1284 NPS users in 
Scotland (827 * 1.56). 
 
However, given the limited nature of the treatment data referring to NPS users, 
and comparing this estimate with the two injecting estimates calculated using the 
Neo data, we would question the robustness of this Scottish estimate as an under-
estimate. As a result, this figure is not reported as a finding in the main report.  
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C. Interview Participant Demographics  
 
 
Pseudonym 
Location (based on 
NHS board) 
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1 Michael Ayrshire & Arran M 26    X  
2 Gary Greater Glasgow & Clyde M 39    X X 
3 Kieran Lothian M 46    X  
4 Steven Ayrshire & Arran M 39    X X 
5 Debbie Ayrshire & Arran F 22     X 
6 Alistair Ayrshire & Arran M 28    X  
7 Nick Ayrshire & Arran M 36     X 
8 Tracey Ayrshire & Arran F 26  X  X  
9 John Ayrshire & Arran M 26  X  X  
10 James Greater Glasgow & Clyde M 19  X   X 
11 Daniel Greater Glasgow & Clyde M 17  X   X 
12 Peter Greater Glasgow & Clyde M 17  X   X 
13 Jacob Lanarkshire M 49    X  
14 Paula Greater Glasgow & Clyde F 32    X X 
15 Andrea Fife F 34  X  X  
16 Moira Fife F 39  X    
17 Jessica Fife F 35  X  X  
18 Tiffany Tayside F 28    X  
19 Nicola Tayside F 32  X    
20 Claire Tayside F 30  X  X X 
21 Christina Tayside F 39  X    
22 Luke Grampian M 20   X   
23 Samuel Dumfries & Galloway M 19   X  X 
24 William Lothian M 55 X   X  
25 Hugh Greater Glasgow & Clyde M 61 X X    
26 Thomas Lothian M 45 X X    
27 Graeme Lothian M 44 X X  X  
28 Kevin Lothian M 35  X    
29 Kimberly Lothian F 32  X  X  
30 Alexander Greater Glasgow & Clyde M 42 X     
31 Michelle Highland F 16   X   
32 Chloe Highland F 17   X   
33 Colin Lanarkshire M 27    X  
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D. Qualitative Data Collection: Topic guides 
Interview Topic Guide 
 
Background Information 
Age:      Ethnicity:   
Gender:    Location:  
 
What I want to do now is focus on the first time you used a legal high... 
 What was it?  
o PROMPT: powder, name on packet, effects told it would have  
 What did you know about it before taking it? 
o PROMPT: source, e.g. online, friends  
o PROMPT: What effects were you expecting from it? 
o PROMPT: did you know what was an active dose? 
 Where did you get it from?  
o Why that source?  
 How did you take it? 
o PROMPT: swallowed, snorted, dabbed, smoked, injected? 
o Why that method? 
 How much did you take? 
o PROMPT: all/portion? Why? 
 Where were you and who were you with?  
 What happened?  
o PROMPT: Using anything else (inc. alcohol) before/during/after? 
o PROMPT: Effects of drug on body (ability to distinguish effects?) 
o PROMPT: Effects of drug on behaviour (ability to distinguish effects?) 
 What led up to you trying it that first time? 
o PROMPT: peers, trauma, curiosity, legality e.t.c. 
o PROMPT: motives about a legal high, or that legal high 
 Had you tried any illegal drugs before you tried it? 
o If yes, was it like any other drug you have tried? 
o If no, did it prompt you to try any illegal drugs? If so, what? 
 What did you particularly enjoy about it that first time?  
 Was there anything you didn‟t like?  
o PROMPT: During 
o PROMPT: After  
 What did you do to help you manage that?  
 Have you been to see anyone for any help with the effects?  
o PROMPTS: A&E, GP, CAT, NSP, friends, family, dealer, internet 
 Have you tried it since then?  
o Why/not?  
 Have you tried any other legal highs since then?  
o GENERATE LIST OF LEGAL HIGHS TRIED 
o How often would you say you take legal highs? 
o Do you take with other substances (inc. alcohol)? 
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And now I want to focus on the last time you tried a legal high 
 What was it? 
 Why did you take it?  
 What did you know about it before taking it? 
o PROMPT: source, e.g. friends, internet 
o PROMPT: did you know what was an active dose? 
 Where did you get it from?  
 How did you take it? 
o PROMPT: swallowed, snorted, dabbed, smoked, injected? 
 How much did you take? 
 Where were you and who were you with?  
 What happened?  
o PROMPT: Using another substances before/during/after? 
o PROMPT: Effects of drug body/behaviour (ability to distinguish 
effects?) 
 
 What did you particularly enjoy about it this last time?  
 Was there anything you didn‟t like?  
o PROMPT: During 
o PROMPT: After  
o PROMPT: longer term 
o PROMPT FOR ALL: physical, mental, relationships, hobbies, job, £ 
 What did you do to help you manage that?  
 Have you been to see anyone for any help with the effects?  
o PROMPT: A&E, GP, CAT, NSP, friends, family, dealer, internet 
 
Ending Questions 
 What help would you have liked to have been available to you that wasn‟t?  
 If you could give one piece of advice to someone about to try a legal high for 
the first time, what would it be?  
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Focus Group Topic Guide 
Background Information 
Role:       Type of service:  
Time in Role:     Geographical location: 
 
Prevalence 
 How common do you think NPS use is among your service users?  
o PROMPT: particular groups?  
o PROMPT: age ranges? Gender? 
o PROMPT: changes over time?  
o PROMPT: specific substances/drug categories? How related to 
certain groups? where use? 
 
Motives 
 How do you know service users use NPS?  
o PROMPT: deliberate disclosure? Accidental? 
 What reasons do they give for use?  
o PROMPT: story of a recent client (anonymised) 
 Have any tried NPS and then not carried on?  
o Why not?  
 Have any active drug users you are working with never tried NPS?  
o Why not?  
 Have any transitioned on to NPS and moved away from traditional drugs?  
o Why?  
 In general terms, how have your service users‟ patterns of use changed 
over the last few years?  
o PROMPT: quantity, route of admin, type of NPS used, polydrug use 
 What is different about motivations for NPS compared to controlled drugs? 
 
Harms 
 What, if any, negative effects have you seen as a result of NPS use? 
o PROMPT: harm to self, close others (fam/friends), wider community? 
o PROMPT: What do you think has caused this?  
o PROMPT: legal harms (e.g. using a substance that was legal but that 
has since been controlled?) 
o PROMPT: have you had experience of users becoming dependent on 
NPS? 
o PROMPT: quantity, route of admin, type of NPS used, polydrug use 
 Has NPS use had an impact on reducing the harms caused by illegal 
drugs?  
o If yes, what ways?  
 How do you support NPS-using service users?  
 What resources would make supporting NPS-using service users easier?  
Ending 
 If you could give one piece of advice to someone (e.g. friend, rather than 
service user) contemplating NPS use, what would it be?   
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E. Focus Group demographics  
NHS Board N % 
Ayrshire & 
Arran 
1 2% 
Borders 1 2% 
Dumfries & 
Galloway 
0 - 
Fife 1 2% 
Forth Valley 1 2% 
Grampian 9 21% 
Greater 
Glasgow & 
Clyde 
11 26% 
Highland 4 10% 
Lanarkshire 2 5% 
Lothian 8 19% 
Orkney 0 - 
Shetland 0 - 
Tayside 2 5% 
Western Isles 0 - 
National Role 2 5% 
Total of 
participants 
42 100% 
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F. Online Surveys 
 
Links to PDF versions of the surveys used in this study are below.   
 
It should be noted that question logic was built in to survey questions, so certain 
questions would only be displayed if participants answered yes to an initial 
question e.g. Have you injected NPS, would then bring up a set of NPS injecting 
questions. 
 
NPS Survey 
Online at: https://issuu.com/scottishdrugsforum/docs/nps_user_survey  
NPS Survey Draw 
Online at: https://issuu.com/scottishdrugsforum/docs/nps_prize_draw 
Staff survey 
Online at: https://issuu.com/scottishdrugsforum/docs/nps_survey_staff  
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How to access background or source data 
 
The data collected for this social research publication may be made available on 
request, subject to consideration of legal and ethical factors. Please contact 
Isla.Wallace@gov.scot for further information.  
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